JBC Papers in Press. Published on July 20, 2018 as Manuscript RA118.004060 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.RA118.004060 Discovery of the final steps in ibogaine biosynthesis

Cytochrome P450 and *O*-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from *Tabernanthe iboga*

Scott C. Farrow¹, Mohamed O. Kamileen¹, Jessica Meades¹, Belinda Ameyaw¹, Youli Xiao², Sarah E. O'Connor¹

From the Department of ¹Biological Chemistry, John Innes Centre, Norwich, UK, NR4 7UH, from the ²CAS Centre for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Shanghai, China, 200000

Running title: Discovery of the final steps in ibogaine biosynthesis

To whom correspondence should be addressed: Sarah E. O'Connor, Fax: 44 (0) 1603450018, e-mail sarah.oconnor@jic.ac.uk

Keywords: *Tabernanthe iboga*, monoterpenoid indole alkaloid, cytochromes P450, *O*-methyltransferase, natural product biosynthesis, plant biochemistry, ibogaine, Illumina sequencing, transcriptomics

ABSTRACT

Monoterpenoid indole alkaloids are a large (ca. 3000 members) and structurally diverse class of metabolites restricted to a limited number of plant families in the order Gentianales. Taber-nanthe iboga or iboga (Apocynaceae) is native to western equatorial Africa and has been used in tra-ditional medicine for centuries. Howard Lotsof is credited with bringing iboga to the attention of Western medicine through his accidental discovery that iboga can alleviate opioid withdrawal symp-toms. Since this observation, iboga has been in-vestigated for its use in the general management of addiction. We were interested in elucidating ibo-gaine biosynthesis to understand the unique reaction steps en route to ibogaine. Furthermore, because ibogaine is currently sourced from plant material, these studies may help improve the ibogaine supply chain through synthetic biology approaches. Here we used next-generation sequencing to generate the first iboga transcriptome, and leveraged homologyguided gene discovery to identify the penultimate hydroxylase and final O-methyltransferase steps in ibogaine biosynthesis, herein named ibogamine 10-hydroxylase (I10H) and noribogaine-10-O-methyltransferase (N10OMT). Heterologous expression in Saccharomyces cerevisiae (I10H) or Escherichia coli (N100MT) and incubation with putative precursors, along with HPLC-MS analysis,

confirmed the predicted activities of both enzymes. Moreover, high expression levels of their transcripts were detected in ibogaine-accumulating plant tissues. These discoveries coupled with our publicly available iboga transcriptome will contribute to additional gene discovery efforts and could lead to the stabilization of the global ibogaine supply chain and to the development of ibogaine as a treatment for addiction.

Monoterpenoid indole alkaloids (MIAs) are a large (ca. 3000) and structurally diverse class of plant specialized metabolites restricted to a limited number of plant families in the order Gentianales with remarkable structural diversity seen in the families Rubiaceae, Loganiaceae and Apocynaceae (1– 3). Tabernanthe iboga or iboga (Apocynaceae) is native to western equatorial Africa and has been used in traditional medicine for centuries. Iboga rootbark is central to the Bwiti religion, including during tribal initiation ceremonies and communal masses and is said to connect members with the sacred and divine (4, 5). Howard Lotsof is credited with bringing iboga to the attention of western medicine through his accidental discovery that iboga root extracts can alleviate opiate withdrawal symptoms and since this observation, iboga has been investigated for its use in the treatment of broad-scale addiction (5, 6).

Tabernanthe iboga produces large quantities of ibogan-type MIAs such as ibogaine and tabernanthine in roots and stems. In contrast, the principle alkaloids of leaves are isoplumerantypes including iboxyphylline and ibophyllidine (7– 10)(FIGURE 1a). Ibogaine is the principle and active pharmacological component of iboga rootbark, and shares a characteristic tryptophan/isoprenoid biosynthetic origin (11) with all other MIAs including the anti-cancer drugs vincristine and vinblastine (1)(FIGURE 1b). Unlike the MIA producing plants found throughout the Apocynaceae, elevated ibogaine concentrations and the preponderance of iboga-type alkaloids in general appears to be a chemotaxonomic characteristic of Tabernanthe iboga (10, 12).

Interestingly, ibogaine and catharanthine the precursor to anti-cancer drugs - are iboga-type alkaloids belonging to two distinct optical series (FIGURE 1c). We recently solved the remaining biochemical steps en route to catharanthine in Catharanthus roseus including a landmark dielsalder cyclization step leading to catharanthine (13). We were interested in understanding the biochemical strategies underpinning the synthesis of the disparate stereochemical ibogaine including a potentially unique cyclization step, and the late stages of ibogaine biosynthesis that are characterized by a net decarboxylation at the 16-position, 10-hydroxylation and 10-O-methylation of the predicted coronaridine precursor (FIGURE 2). Considering the commercial sources of ibogaine are primarily plant based and that therapeutic use is contributing to overharvesting, we were keen on discovering ibogaine biosynthetic genes that could bolster current production strategies or lead to the creation of alternative production platforms through modern synthetic biology approaches. This would have the added benefit of assisting with iboga conservation efforts – a primary concern among members of the Bwiti community (www.ibogainealliance.org/iboga/sustainability).

Here we report the first transcriptome of *Tabernanthe iboga* which we used to identify a cytochrome P450 (P450), herein named ibogamine-10-hydroxylase (I10H), and a *O*-methyltransferase (OMT), herein named noribogaine-10-*O*-methyltransferase (N10OMT), that catalyze the penultimate 10-hydroxylation and

final 10-*O*-methylation steps in ibogaine biosynthesis, respectively. This is the first report of enzymes involved in ibogaine biosynthesis and the hydroxylation at the 10-position of ibogamine and coronaridine by I10H are the first examples of a regio-specific hydroxylation of the iboga alkaloid scaffold. These discoveries coupled with our publicly available iboga transcriptome will contribute to additional gene discovery efforts and could lead to the stabilization of the global ibogaine supply chain and development of ibogaine as a treatment for addiction.

RESULTS

Identification of P450 and OMT gene candidates - Candidates for 10-hydroxylation and 10-O-methylation were identified based on sequence homology to tabersonine 16-hydroxylase (T16H; P98183) and 16-hydroxytabersonine Omethyltransferase (16OMT; B0EXJ8) from C. roseus in a transcriptome of T. iboga. T16H and 16OMT methoxylate tabersonine to form an intermediate that is eventually incorporated into vinblastine and vincristine (FIGURE 1b). Five P450 and six OMT candidates were identified with low to moderate (30% - 62%) sequence identity to T16H or 16OMT, respectively. Amino acid alignments of T. iboga P450s or OMTs with characterized or uncharacterized proteins show conserved canonical features of each protein type including the absolutely conserved cysteine residue responsible for iron coordination in P450s (FIGURE S1) and the multiple sequence motifs of OMTs for SAM binding (FIGURE S2). Phylogenetic trees (FIGURE S3) derived from these alignments showed high bootstrap support for a distinct clade of OMTs or P450s belonging to MIA producing plants. For example, T16H is a member of the CYP71 family of P450s and formed a clade with iboga CYP71 candidates suggesting an evolutionary linkage and possible functional similarity. Similarly, 16OMT formed a clade with OMT candidates from iboga and other MIA producing plants indicating a possible functional relationship.

Identification of I10H and N10OMT – P450s were expressed in and enriched from yeast microsomes and screened for activity with MIAs from the plumeran, isoplumeran and ibogan subtype scaffolds (FIGURE 1). HPLC-MS analysis

detected a gain of 16 atomic mass units (amu) in the products of assays with P450 candidate 3 and ibogamine, coronaridine and the synthetic substrate 18-methoxycoronaridine (18-MC). The reaction with this p450 and ibogamine yielded a product that co-eluted with and shared the same MS/MS spectrum as authentic noribogaine, indicating that the product of this reaction is noribogaine and prompted us to name the protein I10H (FIGURE 3A-D). The reaction products of assays with I10H and coronaridine yielded a product that was identified as 10-hydroxycoronaridine based on a comparison of MS/MS spectra to limited published data (14) and the predicted regiospecificity of I10H for the 10position of the ibogan scaffold (FIGURE 3E-H). The low concentration of product in assays with I10H and the synthetic 18-MC precluded product identification, though it is likely that hydroxylation occurs at the 10-position as with other active substrates to yield a previously unreported compound. All other P450 candidates were assayed with the same suite of substrates; however, no other reaction products were identified by HPLC-MS. Interestingly, the 11-O-methyl ether of ibogamine - tabernanthine also occurs in iboga, however, none of the P450s tested showed activity towards the 11-position of ibogamine, suggesting the enzyme responsible for this reaction might belong to a different enzymetype.

His-tagged OMTs were purified using a His-TRAP Ni²⁺ affinity column and size exclusion chromatography (FIGURE S4). Purified OMTs were screened for activity with the suite of MIAs tested for P450 activity. HPLC-MS analysis detected a gain of 14 amu in the products of assays with OMT candidate 1 and both noribogaine and 10hydroxycoronaridine. The reaction with OMT candidate 1 and noribogaine yielded a product that coeluted with and shared the same MS/MS spectrum as authentic ibogaine, leading us to identify the product of this reaction as ibogaine and prompted us to name the protein N10OMT (FIGURE 4A-D). The reaction products of assays with N10OMT and 10-hydroxycoronaridine co-eluted with and shared the same MS/MS spectrum as authentic voacangine (FIGURE 4E-H). Furthermore, the production of voacangine in assays with N10OMT and 10hydroxycoronaridine supported our identification of 10-hydroxycoronaridine from assays with I10H and coronaridine (FIGURE 3). To further validate our results, we co-incubated I10H and N10OMT with ibogamine. This reaction yielded two products that co-eluted with and shared the same MS/MS spectrum as authentic noribogaine or ibogaine, consistent with a stepwise biochemical reaction (FIGURE 5A-H). No reaction products were detected by HPLC-MS with any of the other OMT candidates and the same substrates.

Substrate Specificity – The percent maximum conversion of I10H was highest with the ibogan-type alkaloid ibogamine (100%), but moderate (31%) activity was also detected with coronaridine. Trace hydroxylation activities below 1% were detected with the semi-synthetic substrate 18-MC. N10OMT catalyzed the 10-*O*-methylation of two substrates including relatively low turnover of noribogaine (3%) compared to high turnover of 10-hydroxycoronaridine (100%) (FIGURE 6).

Reaction Kinetics and pH optimum – I10H exhibited a K_m value of 11.4 \pm 1.87 μM with ibogamine, whereas N10OMT displayed a K_m value of 73.6 \pm 28.5 μ M with noribogaine. Approximate V_{max} values of 14 ± 1.84 pmol s⁻¹ mg⁻¹ for N10OMT were calculated using noribogaine as the substrate with a catalytic efficiency of 7.45 ± 3.05 M^{-1} s⁻¹ (Table 1). Low quantities or inaccessibility of other substrates prevented additional kinetics experiments. Furthermore, the microsomal nature of I10H precluded the calculation of additional kinetic constants (FIGURE 7A and B). The pH optimum for I10H with ibogamine and N10OMT with noribogaine were approximately 8 and 9, respectively, which is consistent with other reported optima for P450s and OMTs (15–17) (FIGURE 7C and D).

RT-qPCR analysis of I10H and N10OMT – The gene expression of I10H and N10OMT in different organs of T. iboga were examined using RT-qPCR (FIGURE 8). I10H expression was highest in the root and stem compared to leaf and cotyledon, which showed significantly lower expression (ANOVA with Tukey PHT, p < 0.05). Gene expression of N10OMT was highest in stem and root followed by young leaf, first true leaf and cotyledon; however, N10OMT was not significantly different in any of the tissues (ANOVA with Tukey PHT, p < 0.05).

Metabolite analysis of iboga plant organs – Selected alkaloids were profiled using HPLC-MS and displayed a tissue specific distribution comparable with previous reports (7–10). In general, ibogatype alkaloids were highest in root, stem and cotyledon, with the exception of coronaridine, which was low in cotyledon, and noribogaine, which was low in all of these tissues. Alternatively, these compounds were markedly lower or not detected in leaf tissue, where the distinguishing alkaloids were tentatively identified as ibophyllidine and iboxyphylline based on previous reports (7, 10) (FIGURE 9).

DISCUSSION

Tabernanthe iboga (iboga) is the main commercial source of ibogaine, the pharmacologically active alkaloid of iboga rootbark that is being investigated for its anti-addictive properties (6). Because ibogaine is currently sourced from plant material, we are interested in simultaneously contributing to improvements in the ibogaine supply chain and developing new synthetic biology applications for gaining access to novel small molecule therapeutics based on the ibogaine scaffold. Here we report the first insights into ibogaine by reporting the transcriptome for *T. iboga* and the subsequent discovery of the decorating enzymes that modify the indole scaffold with a methoxy group.

We used next generation sequencing to generate an iboga transcriptome, and leveraged homology dependent gene discovery to identify five cytochromes p450 and six OMT candidates that shared low (30%) to moderate (62%) amino acid sequence identity with tabersonine 16-hydroxylase or 16-hydroxytabersonine-O-methyltransferase, enzymes involved in vinblastine biosynthesis in Catharanthus roseus, the only other Apocynaceae plant for which an alkaloid hydroxylase/methyl transferase pair has been reported (FIGURE 1B). We expressed these candidates in S. cerevisiae (P450s) or E. coli (OMTs) and tested them with available substrates. Although the vinblastine precursor, tabersonine, that is hydroxylated does not chemically resemble ibogaine, one P450 with homology to T16H showed hydroxlyase activity with ibogamine (FIG-URE 3A-D) suggesting that it was responsible for the penultimate step in ibogaine biosynthesis. Similarly, one OMT showed O-methylation activity towards the product of this hydroxylase, noribogaine (FIGURE 4A-D), demonstrating its ability to catalyze the final step in ibogaine biosynthesis. When both proteins were incubated with ibogamine, we observed the production of two products consistent with authentic noribogaine or ibogaine, respectively (FIGURE 5A-H). The regiospecificity of both proteins for the 10-postion of the ibogan scaffold prompted us to rename these proteins ibogamine-10-hydroxylase (I10H) and noribogaine-10-*O*-methyltransferase (N10OMT). I10H and N10OMT failed to turnover any other MIA that was tested.

Notably, this is the first example of a regiospecific 10-hydroxylation of an indole alkaloid scaffold, and also the first example of a hydroxylation of the iboga alkaloid motif. I10H is therefore an important addition to the biocatalytic toolbox for alkaloid derivatisation. For example, when compared to ibogaine, the 10-hydroxylated derivative – noribogaine - has shown promising results for treating addiction without some of the cardiac side effects (18). As such, I10H could be employed biocatalytically to produce this therapeutic and analogues thereof. Similarly, the trace 10-hydroxylase activity of I10H with the semi-synthetic ibogaine analogue 18-MC, which also has distinct activity profiles, could be improved by protein engineering, leading to newto-nature ibogaine analogues with potentially novel biological activities. Sequence alignments of I10H with other alkaloid hydroxylases did not reveal any obvious amino acids responsible for switching of substrate and regioselectivity, highlighting the challenges of engineering this class of enzyme.

The roles of I10H and N10OMT in ibogaine biosynthesis in planta are supported by both their high expression levels in iboga tissues accumulating ibogaine (FIGURE 8) along with the high affinity (11 μ M) of I10H and moderate affinity (73 μ M) of N10OMT with ibogamine or noribogaine, respectively. However, it is important to note that the 10-hydroxylation activity of I10H and 10-O-methylation activity of N10OMT with the alternative substrate coronaridine and 10-hydroxycoronaridine, respectively, coupled with the presence of the downstream product voacangine in iboga strongly suggests that I10H and N10OMT have dual roles in two branches of ibogaine biosynthesis (FIGURE 2). We speculate that the decarboxylation of both coro-

naridine and voacangine could contribute to ibogaine concentrations in the plant. This hypothesis is underscored when comparing the relative activity of N10OMT with 10-hydroxycoronaridine and noribogaine and I10H with coronaridine and ibogamine, which taken together suggest the pathway proceeds through both coronaridine and voacangine. This would be analogous to morphine biosynthesis, where thebaine bifurcates via 6-O or 3-O-demethylation to form codeinone or oripavine, respectively, both en route to morphine(19). Furthermore, considering the higher content of voacangine relative to ibogaine in members of the Tabernaemontana and Voacanga genera, it will be interesting to test the substrate preference of I10H homologs from related plants to pinpoint any chemotaxonomic differences of these P450s among species. However, although we tested six OMTs with moderate to high sequence identity to T16OMT, we cannot absolutely discount an additional OMT with higher relative activity for noribogaine compared to 10hydroxycoronaridine.

With the rise of the global opiate drug epidemic, treatment of opiate addiction is a growing concern. To date, there are few effective treatments for opiate addiction and this has spawned research into psychedelic compounds with potential for treating addiction, as well as mental illnesses. In this context, ibogaine has shown promising results for the treatment of opiate and broad-scale addiction, however, the stigma associated with psychedelic medicines like ibogaine is a major hurdle for its acceptance as a mainstream treatment option. Furthermore, there are reports of potentially harmful side-effects of ibogaine use. In this regard, discovery of ibogaine biosynthetic genes has the potential to develop synthetic biology application that could streamline production strategies or create access to new-to-nature compounds that treat addiction without some of the side-effects. Moreover, iboga also produces isoplumeran-type MIAs such as ibophyllidine and iboxyphylline (FIGURE 1) (20), and the transcriptomic data reported here will also be key for elucidating the enzymatic underpinnings of these unique backbones. In sum, discovery of I10H and N10OMT expands the toolkit of functionalizing enzymes for the aromatic ring of MIAs, furthering the potential for tailor-made therapeutics.

EXPERIMENTAL PROCEDURES

Plant Material — *Tabernanthe iboga* seeds were acquired from the global ibogaine therapy alliance (www.ibogainealliance.org) in May of 2014. Seeds were imbibed with warm (37 °C), sterile water for 48 hrs and sown in a matrix consisting of coconut coir, sharp sand and perlite (5:4:1). Seeds were kept moist and at a constant temperature (30 °C) until radicle emergence (2-4 weeks). Seedlings were grown at a constant temperature (30 °C) under a 12 hr LED light cycle (Kyson LED grow light) and watered every two days with 50 ml of sterile water. The growing regime was maintained until the emergence of the first leaves, whereby plants were supplemented with 50 ml of fertilizer (BIO-BIZZ) bi-weekly.

Chemicals and Reagents — All solvents used for extractions and preparative HPLC were of HPLC grade, whilst solvents for HPLC-MS analysis were of MS grade. All solvents were purchased from Fisher Scientific. Ibogaine, noribogaine, ibogamine, voacangine and 18-methoxycoronaridine were gifts from Dr. Kenneth Alper (NYU Langone Health). Coronaridine was isolated from the stem bark and roots of Tabernaemontana divaricata with modifications to (21). Briefly, plant material was macerated in methanol and the extract was filtered through Whatman paper and dried in vacuo. The residue was resuspended in 0.01 M HCl and extracted with ethyl acetate to remove hydrophobic impurities. The aqueous extract was adjusted to pH 10 (4 M potassium carbonate) and alkaloids were extracted with ethyl acetate. The ethyl acetate fraction was dried in vacuo and resuspended in methanol, and coronaridine was purified using semi-preparative HPLC using a Dionex Ultimate 3000 HPLC and UV detector (284 nm).

Coronaridine was eluted from a waters XBridge semi-prep C18 column (10 x 200 mm, 5 μ m in a gradient of 0.1% ammonia and acetonitrile beginning with a 5-minute hold period (80:20, 0.1% ammonia:acetonitrile) and changing linearly to 50% acetonitrile in 10 minutes, 65% acetonitrile by 60-minutes, 75% acetonitrile by 62 minutes and 95% acetonitrile by 62.1-minutes. Conditions remained at 95% acetonitrile for 2 minutes and the column was re-equilibrated in starting conditions for 6-minutes. The fraction containing

coronaridine was dried in a GeneVac (SP Scientific) and resuspended in methanol. The concentration of coronaridine was calculated using the molar extinction co-efficient from (22). The identification of coronaridine was confirmed using highresolution mass spectrometry and ¹H/¹³C NMR (Table S3). 10-hydroxycoronaridine was prepared enzymatically by feeding coronaridine to Saccharomyces cerevisiae expressing I10H. Briefly, a yeast starter culture was grown overnight in synthetic complete drop-out media (-leucine) with 2% glucose. I10H expression was induced by adding 100 μ l of starter culture to 1 ml of synthetic complete dropout media (-leucine) containing 0.2% glucose, 1.8% galactose, 100 mM HEPES pH 7.5, and approximately 350 µg coronaridine. Cultures were grown for an additional 48 hrs, whereby yeast was pelleted and the supernatant was collected. The pellet was extracted with 500 µl MeOH and vigorous vortexing for 1 minute, whereby debris was pelleted by centrifugation and the supernatants were pooled. The supernatant was dried under vacuum in a GeneVac and 10-hydroxycoronaridine was purified via semi-preparative chromatography according to the HPLC method above. The concentration of 10-hydroxycoronaridine was calculated using the molar extinction co-efficient from (14). All gene and fragment amplifications were performed using Platinum Superfi polymerase whilst colony PCRs were performed using Phire II master mix (Thermo Fisher). PCR product purifications were performed using the Macherey Nagel PCR clean-up kit. Plasmid purifications were performed using Promega Wizard minipreps. cDNA was prepared using Superscript IV VILO master mix and ezDNase (Thermo Fisher). RT-qPCR was performed using Sensi-FAST Sybr No-ROX kit (Bioline). The In-fusion HD cloning kit was from Clontech.

Tabernanthe iboga transcriptomics and library construction — Iboga seedlings (3 months) were ground to a fine powder under liquid nitrogen using a tissue lyser (Qiagen). RNA was extracted from 100 mg of powdered tissue using a modified CTAB method (23). RNA quality was assessed by visualizing 28S and 18S quality on an agarose gel and UV absorption ratios, where only samples with ratios above 2.0 (260/280 nm) and 2.2 (260/230 nm) were used. RNA was shipped to BGI (Hong Kong)

for quality control, cDNA library construction, sequencing (HiSEQ4000 with PE150), and *de novo* transcriptome assembly.

Gene isolation, phylogenetic analysis and expression vector construction — T. iboga leaves, cotyledons, stems and roots were flash frozen in liquid nitrogen and powdered with the assistance of a tissue lyser. RNA was extracted from powdered tissue using the CTAB method described in (23), and cDNA was synthesized from a mixture of root, stem, cotyledon and leaf RNA using SuperScript IV VILO master mix with ezDNAse according to the manufacturers protocol. Translated Tabernanthe iboga transcriptome databases were searched using T16H (P98183) and 16OMT (B0EXJ8) protein sequences as queries to identify candidates for 10hydroxylation of ibogamine and 10-O-methylation of noribogaine. Amino acid sequence alignments were performed with MAFFT (24), and phylogenetic relationships were analyzed using Geneious 9 (Biomatters Ltd., Auckland, New Zealand). Five P450 and six OMT cDNAs amplified by RT-PCR with SuperFi DNA polymerase using primers with flanking In-fusion sites (Table S1). P450 and OMT PCR products were ligated into the pESC-leu2Δ (P450s) vector containing a cytochrome P450 reductase from Artemesia annua (25) or pOPINF (OMTs) using the manufacturers In-fusion protocol. Assembled vectors were transformed into Stellar competent cells (Clontech), whereby positive transformation was confirmed using colony PCR with primers listed in Table S1. Sequences were confirmed using Eurofins sequencing service (Clontech). Sequenced confirmed plasmids were transformed into Saccharomyces cerevisiae strain PEP4 (P450s) or Escherichia coli expression strain SoluBL21 (OMTs).

Protein Expression and purification — Starter cultures of *E. coli* harboring OMT:pOPINF constructs were grown overnight at 37 °C. A 1:100 dilution was made by adding overnight culture to 11 of 2YT media containing 50 μ g.ml⁻¹ carbenicillin. Protein expression was induced at OD600 A=0.7 by adding IPTG to a final concentration of 300 μ M. Protein expression continued at 18 °C for 16 hrs whereby cells were harvested by centrifugation (4000 rpm). Bacterial pellets were resuspended in 50 ml of protein extraction buffer (A1

buffer,50 mM TRIS, 50 mM glycine, 5% glycerol v/v, 0.5 M NaCl, 20 mM imidazole) containing 10 mg lysozyme (Sigma, L6876) and 1 tablet of cOmplete EDTA free protease inhibitor (Roche). Cells were lysed at 4 °C using a cell disruptor (25 KPI) and centrifuged at 35,000g to remove insoluble debris. The supernatant was filtered through a 0.45 μ m glass syringe filter and applied to a HIS-Trap Ni-affinity column with the assistance of an AKTA pure FPLC. The protein-charged resin was washed with 20 column volumes of A1 buffer, and protein was eluted with B1 buffer (A1 buffer + imidazole to a final concentration of 500 mM). OMTs were subjected to a further purification step on a SEC-1660 gel filtration column and buffer exchanged in A4 buffer (20 mM HEPES, 150 mM NaCl, pH 7.5). Each OMT (2 μ g) was separated by SDS-PAGE to assess protein yield and purity (FIGURE S4). Final protein concentrations used for enzyme assays were calculated using the theoretical protein extinction coefficient, molecular weight and absorbance on a nanodrop.

Freshly transformed yeast cultures harbouring pESC-leu2\Delta constructs were grown on an orbital shaker (250 rpm) to log phase in 50 ml of Synthetic Complete dropout medium lacking leucine (SC-leu) and 2% (w/v) glucose. Cultures were subsequently centrifuged (4,000g) and resuspended in 11 of protein induction medium containing SC-leu supplemented with 0.2% (w/v) glucose and 1.8% (w/v) galactose. Cultures were grown for an additional 24 h at 30 °C and cells were harvested by centrifugation. Microsomes were prepared based on a standard protocol. Briefly, after initial treatment with TEK buffer (5 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 100 mM NaCl, 20 mM KCl, 10 mM MgCl₂), cells were re-suspended in 5 ml of cold TESB (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, sorbitol) in a 50 ml tube. Yeast cells were lysed at 4 °C with a cell disruptor (25 KPI) and insoluble debris was removed by centrifugation at 30,000g. The supernatant was subjected to sucrose-gradient separation of microsomes by ultracentrifugation for 1 h at 35,000g and 4 °C. Microsomal pellets were re-suspended in 1 ml of TEG buffer (pH 7.5) and assayed immediately or stored at -80 for future use. I10H expression was confirmed using proteomics of microsomal preparations whereby two unique peptides were detected (Peptide 1: NVFQETGN-

VDETK, mass:1479.6842; Peptide 2: NVFQET-GNVDETKLGELK, mass:2020.0113).

N10OMT and I10H Assays — A selection of available MIAs were screened in triplicate as potential substrates for OMTs and P450s using a standardized assay. For each screen, 50 µg of purified and desalted OMT or 20 µl of purified microsome containing the P450 was incubated for 16 h at 30 °C with 25 μ M of candidate substrate and 100 μ M SAM (OMT) or 100 μ M NADPH (P450), in 50 mM HEPES, pH 7, in a total reaction volume of 100 μ l. Denatured proteins were used as negative controls. Assays were quenched with 2 volumes of methanol, and samples were reduced to dryness in a GeneVac and resuspended in 1.5 ml of HPLC running buffer (0.1% formic acid:methanol, 50:50 v/v). MIAs accepted as substrates were used to determine relative conversion rates using identical assay conditions except for an incubation time of 25 min, which was within the linear range of each assay, a final alkaloid substrate concentration of 20 µM, and a total reaction volume of 100 μ l. Assay pH was also adjusted to 8 for p450 assays and 9 for OMT assays based on empirical pH optimum. Samples were diluted to 1.5 ml with HPLC running buffer and analysed by HPLC-MS. Noribogaine and ibogamine were used to determine kinetic parameters for N10OMT and I10H, respectively, at concentrations up to 500 μ M. Samples were diluted with HPLC running buffer to a final substrate concentration of 1 μ M for analysis by HPLC-MS.

Analysis of Enzyme Assays — Enzyme assays were analyzed by HPLC-MS using an Acquity UPLC coupled with a XEVO TQS (Waters). For substrate range and relative activity analyses, 1 μ l of sample, was injected onto a Acquity BEH C18 column (1.7 μ m, 2.1 x 50 mm), and analytes were eluted with a gradient of running buffer (0.1% formic acid; solvent A) and acetonitrile (solvent B). The flow rate was 600 μ l min⁻¹, and the gradient began with 2% solvent B and increased linearly to 98% solvent B by 7 minutes. The mobile phase composition remained constant until 8.1 minutes at which time it returned immediately to 0% solvent B followed by a 2 minutes re-equilibration period. Analytes were subjected to positive electrospray ionization using source conditions optimized for MIAs (Capillary voltage: 3.0 kV, Source Temp: 150 °C; Desolvation Temp: 500 $^{\circ}$ C; Cone gas: 50 1 h⁻¹; Desolvation gas: 800 1 h⁻¹) and were subsequently detected by multiple reaction monitoring (MRM) with conditions for each analyte (Table 2). MRM conditions were determined using the waters Intellistart software by injecting standards into the waters mass spectrometer. Transition giving the highest intensity peaks were selected for MRM panels in figures 3-5. Relative enzyme activity was calculated as the percent turnover of each substrate using the following formula: Product peak area ÷ (Substrate peak area + Product peak area) x 100. Subsequently, the compound with the highest turnover for each protein was set to 100%, and the detected activity with all other substrates was expressed as a percentage of the maximum. For kinetic parameter analyses, a five-point calibration curve of noribogaine or ibogaine (500 pM to 5 μ M) was established to semi-quantitatively determine the amount of product formed per unit of time. Kinetic constants were calculated based on Michaelis Menten kinetics using Prism 5 (GraphPad Software, La Jolla,CA).

Reaction Product Identification — Comparison of collision induced dissociation (CID) spectra with empirical spectra either from authentic standards or available in the literature was used to identify each enzymatic reaction product (FIGURE 3-5). CID was performed at 40 eV for each compound, and product ions were detected between 50 m/z and 5-10 atomic mass units above the m/z of the quasi-molecular ion. CID was carried out using the HPLC-MS method above with the exception of changing the scan mode to MS2 scan.

RT-qPCR — *T.iboga* root, stem, cotyledon, first true leaf, and young leaf were flash frozen in liquid nitrogen and powdered with the assistance of a tissue lyser. RNA was extracted from each tissue using the CTAB method described in (23). 700ng of total RNA from each sample was treated with ezD-NAse and reverse transcribed using VILO superscript IV according to the manufacturers protocol. Relative transcript abundance for each tissue was de-

termined by RT-qPCR and expressed as $2^{-\Delta Ct}$ on a BioRad CFX96 Q-PCR instrument using the cDNA synthesized above and the primers listed in Table S2. Three biological replicates and three technical replicates were analyzed for each gene using the reference gene: N2227-like family protein, N2227. Efficiencies for all primer sets were approximately equal and always >90%. Analysis was performed in excel.

Metabolite Analysis — A frozen and pulverized aliquot of each tissue was collected in preweighed microfuge tubes and extracted with 1 ml of methanol spiked with 1 μ g ml⁻¹ ajmaline. Alkaloids were extracted for 1 minute with vigorous vortexing and sonication followed by centrifugation (14,000g for 1 minute) to remove insoluble debris. The supernatant was passed through a 0.22 μ m membrane and diluted 1:4 with 0.1% formic acid:methanol (50:50 v/v) in a 2 ml glass auto-sampler vial. HPLC-MS analysis was performed on a Shimadzu LCMS-IT-TOF Mass Spectrometer coupled to a Nexera 2 chromatographic system. Chromatographic separation was carried out using a Kinetex XB-C18 column (2.6 μ m, 100 × 2.10 mm; Phenomenex) using a binary solvent system consisting of solvent A (0.1% formic acid), and solvent B (acetonitrile). Compounds were eluted with a linear gradient of 10% to 30% solvent B in 5 minutes. The column was washed with 100% B for 1.5 minutes and re-equilibrated to 10% B for 2.5 min before the next injection. The flow rate was set at 600 μ l min⁻¹ and the Injection volume was 1 μ l. Mass spectrometry was performed in positive ion mode scanning from 150–1,200 m/z. The source settings were: heat block temperature 300 °C, nebulizing gas flow 1.41 min⁻¹, CDL temperature 250 °C, detector voltage 1.6 kV. Data analysis was performed using the Shimadzu Profiling Solution software, and normalization of data was accomplished using tissue weight. Furthermore, ajmaline detection via MS did not vary beyond 5%.

Acknowledgments: We gratefully acknowledge Dr. Kenneth Alper of New York University for providing authentic standards and Jonathan Dickinson of the global ibogaine alliance for providing *Tabernanthe iboga* seeds. We are grateful to Dr. Gerhard Saalbach of the John Innes Proteomics Centre for proteomics work. We thank Dr. Benjamin Lichman for helpful discussions on NMR. Author contributions: S.C.F characterized all proteins, purified substrates, coordinated all experiments; M.K. performed SDS-PAGE and

protein purification. J.M. helped with initial cloning and characterization of I10H and N10OMT; B.A. helped with cloning; S.C.F and S.E.O. wrote manuscript; S.F., M.O.K., S.E.O., and Y.X. revised manuscript. T16H (P98183) and 16OMT (B0EXJ8). The GenBank accession numbers for I10H and N10OMT are MH454074 and MH454075, respectively. Transcriptome data has been deposited in Dryad (deposition number DOI: 10.5061/dryad.2mh70m2). S.C.F acknowledges an EMBO long-term fellowship and S.E.O. and Y.X. acknowledges the CAS-BBSRC alliance for funding.

Conflict of interest: The authors declare that they have no conflicts of interest with the contents of this article.

REFERENCES

- 1. O'Connor, S. E. and Maresh, J. J. (2006) Chemistry and biology of monoterpene indole alkaloid biosynthesis. *Nat. Prod. Reports* **23**, 532–547
- 2. Ziegler, J. and Facchini, P. J. (2008) Alkaloid biosynthesis: metabolism and trafficking. *Annu. Rev. Plant Biol.* **59**, 735–769
- 3. Hagel, J. M., Yeung, E. C., and Facchini, P. J. (2008) Got milk? The secret life of laticifers. *Trends Plant Sci.* **13**, 631–639
- 4. Pope, H. G. (1969) *Tabernanthe iboga*: an African narcotic plant of social importance. *Econ. Bot.* **23**, 174–184
- 5. Alper, K. R., Lotsof, H. S., and Kaplan, C. D. (2008) The ibogaine medical subculture. *J. Ethnopharmacol.* **115**, 9–24
- 6. Alper, K. R. (2001) Ibogaine: A review. Alkaloids Chem. Biol. 56, 1–38
- 7. Khuong-Huu, F., Cesario, M., Guilhem, J., and Goutarel, R. (1976) Alcaloides indoliques—CII. *Tetrahedron* **32**, 2539–2543
- 8. Mulamba, T., Delaude, C., Le Men-Olivier, L., and Lévy, J. (1981) Alcaloides de *Tabernanthe pubescens*. *J. Nat. Prod.* **44**, 184–189
- 9. Delaude, C., Huls, R., Breyne, H., Thepernier, P., Massiot, G., and Le Men-Olivier, L. (1984) D'un hybride intergenerique fertile de la famille des apocynacees. *Bull. de la Société Royale des Sci. de Liège* **53**, 206–214
- 10. Bisset, N. G. (1989) Series of revisions of Apocynaceae: 29. A taxonomic revision of the genus Tabernanthe and a study of wood anatomy of *T. iboga. Wageningen Agric. Univ. Pap.* **89**, 1–18
- 11. Yamasaki, M. and Leete, E. (1964) Biosynthesis of the Iboga alkaloids: The incorporation of tryptophan-3-C¹⁴ into ibogaine. *Tetrahedron Lett.* **5**, 1499–1501
- Tang, B.-q., Wang, W.-J., Huang, X.-j., Li, G.-q., Wang, L., Jiang, R.-w., Yang, T.-t., Shi, L., Zhang, X.-q., and Ye, W.-c. (2014) Iboga-type alkaloids from *Ervatamia officinalis*. *J. Nat. Prod.* 77, 1839–1846
- 13. Caputi, L., Franke, J., Farrow, S. C., Chung, K., Payne, R. M., Nguyen, T. D., Dang, T. T. T., Carqueijeiro, I. S. T., Koudounas, K., de Bernonville, T. D., Ameyaw, B., Jones, D. M., Vieira, I. J. C., Courdavault, V., and O'Connor, S. E. (2018) Missing enzymes in the biosynthesis of the anticancer drug vinblastine in Madagascar periwinkle. *Science* **60**, 1235–1239
- 14. Gunasekera, S. P., Cordell, G., and Farnsworth, N. R. (1980) Anticancer indole alkaloids of *Ervatamia heyneana*. *Phytochemistry* **19**, 1213–1218
- 15. Farrow, S. C., Hagel, J. M., Beaudoin, G. A., Burns, D. C., and Facchini, P. J. (2015) Stereochemical inversion of (*S*)-reticuline by a cytochrome P450 fusion in Opium poppy. *Nat. Chem. Biol.* **11**, 728–732
- 16. Dang, T.-T. T. and Facchini, P. J. (2012) Characterization of three *O*-methyltransferases involved in noscapine biosynthesis in opium Poppy. *Plant Physiol.* **159**, 618–631
- 17. Nomura, T. and Kutchan, T. M. (2010) Three new *O*-methyltransferases are sufficient for all *O*-methylation reactions of ipecac alkaloid biosynthesis in root culture of *Psychotria ipecacuanha*. *J. Biol. Chem.* **285**, 7722–7738
- 18. Carnicella, S., He, D. Y., Yowell, Q. V., Glick, S. D., and Ron, D. (2010) Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. *Addict. Biol.* **15**, 424–433
- 19. Hagel, J. M. and Facchini, P. J. (2010) Dioxygenases catalyze the *O*-demethylation steps of morphine biosynthesis in opium poppy. *Nat. Chem. Biol.* **6**, 273–275
- 20. Szabó, L. (2008) Rigorous biogenetic network for a group of indole alkaloids derived from strictosidine. *Molecules* **13**, 1875–1896
- 21. Rastogi, K., Kapil, R. S., and Popli, S. P. (1980) New alkaloids from *Tabernaemontana divaricata*.

- Phytochemistry 19, 1209–1212
- 22. Okuyama, E., Gao, L. H., and Yamazaki, M. (1992) Analgesic components from bornean medicinal plants, *Tabernaemontana pauciflora* Blume and *Tabernaemontana pandacaqui* Poir. *Chem. & Pharm. Bull.* **40**, 2075–2079
- 23. Meisel, L., Fonseca, B., González, S., Baeza-Yates, R., Cambiazo, V., Campos, R., González, M., Orellana, A., Retamales, J., and Silva, H. (2005) A rapid and efficient method for purifying high quality total RNA from peaches (*Prunus persica*) for functional genomics analyses. *Biol. Res.* 38, 83–88
- 24. Katoh, K. and Standley, D. M. (2013) MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780
- 25. Ro, D.-K., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. a., Eachus, R. a., Ham, T. S., Kirby, J., Chang, M. C. Y., Withers, S. T., Shiba, Y., Sarpong, R., and Keasling, J. D. (2006) Production of the antimalarial drug precursor artemisinic acid in engineered yeast. *Nature* **440**, 940–943

FOOTNOTES

Funding: This work was supported by grants from BBSRC (BB/J004561/1) (S.E.O.and Y.X.) S.C.F gratefully acknowledges postdoctoral funding (ALTF 846-2016) an EMBO Long term Fellowship. Abbreviations: 18-methoxycoronaridine, 18-MC; 16-hydroxytabersonine *O*-methyltransferase, 16OMT; atomic mass units, amu; cytochromes P450, P450; ibogamine-10-hydroxylase, I10H; monoterpene indole alkaloids, MIAs; multiple reaction monitoring, MRM; noribogaine-10-*O*-methyltransferase, N10OMT; tabersonine 16-hydroxylase, T16H; *O*-methyltransferase, OMT)

TABLES

Table 1: Kinetic values for I10H and N10OMT with ibogamine and noribogaine, respectively

| Enzyme | $K_m (\mu M)$ | V_{max} | k _{cat} | k _{cat} /Km |
|--------|-----------------|-------------------------|---|----------------------|
| | | $(pmol s^{-1}.mg^{-1})$ | (s^{-1}) | $(M^{-1}.s^{-1})$ |
| I10H | 11.4 ± 1.87 | - | - | - |
| N10OMT | 73.6 ± 28.5 | 14 ± 1.84 | $5.48 \times 10^{-4} \pm 7.23 \times 10^{-5}$ | 7.45 ± 3.05 |

 Table 2: Parameters Used for Multiple Reaction Monitoring

| | | | | 0 | |
|------------------------|---------------|---------------|---------------|--------------|------------------|
| Compound | Precursor Ion | Product Ion 1 | Product Ion 2 | Cone Voltage | Collision Energy |
| | m/z | m/z | m/z | V | eV |
| Voacangine | 369.2 | 122.1 | 174.1 | 26 | 40 |
| 18-hydroxycoronaridine | 369.2 | 130.1 | 144.2 | 26 | 40 |
| Coronaridine | 339.2 | 130.1 | 144.2 | 26 | 30 |
| 10-Hydroxycoronaridine | 355.2 | 146.1 | 160.1 | 26 | 40 |
| Ibogamine | 281.2 | 122.1 | 144.1 | 26 | 36 |
| Noribogaine | 297.2 | 122.1 | 160.1 | 26 | 30 |
| Ibogaine | 311.2 | 122.1 | 173.9 | 26 | 30 |

FIGURES





Figure 1: Alkaloids of iboga (**A**). The principle ibogan-type alkaloids Ibogaine (with C10 *O*-methyl group highlighted in red) and tabernanthine are abundant in the root and stems, whereas the isoplumeran-type alkaloids ibophyllidine and iboxyphylline are the core alkaloids present in leaves. Anti-cancer drugs synthesized in *Catharanthus roseus* with C11 *O*-methyl group of the vindoline moiety highlighted in red (**B**). Ibogaine and catharanthine are ibogan-type alkaloids belonging to opposing optical series (**C**).

Figure 2: Proposed biosynthetic pathway to ibogaine in *Tabernanthe iboga*. Tryptophan and geranyl diphosphate undergo multiple transformations (multiple arrows) to yield strictosidine, which undergoes multiple transformations (multiple arrows) to yield the hypothesized reactive intermediate dehydrosecodine. Dehydrosecodine is thought to undergo cyclization to form the ±-ibogan scaffolds, which in iboga, eventually forms (-)-coronaridine. Net decarboxylation of coronaridine yields ibogamine, which can then undergo 10-hydroxylation and 10-*O*-methylation to yield ibogaine. The pathway could also bifurcate through voacangine, whereby net decarboxylation of voacangine could lead to ibogaine. Percentages and arrow thickness indicate the relative activity of I10H and N10OMT for different substrate in the pathway underscoring the potential routes to ibogaine. Red arrows represent the steps that are the focus of this study.



respectively. HPLC-MS chromatograms and MS/MS spectra of authentic standards and products from enzyme assays with I10H and ibogamine or coronaridine. HPLC-CID chromatogram of noribogaine Standard (A). HPLC-CID chromatogram of EV and ibogamine (black-line) and reaction product from I10H and ibogamine assay (green-line) that co-elutes with authentic noribogaine (B). MS/MS spectra of noribogaine standard (top; C) and mirrored MS/MS spectra of the product from the I10H and ibogamine assay (bottom; C). Multiple reaction monitoring of the assay with I10H and ibogamine (D) showing the production of noribogaine under standard reaction conditions (A). HPLC-CID chromatogram of coronaridine Standard (E). HPLC-CID chromatogram of EV and coronaridine (black-line) and reaction product from I10H and coronaridine assay (green-line) that co-elutes with 10-hydroxycoronaridine (F). MS/MS spectra of 10-hydroxycoronaridine (top; G) and mirrored MS/MS spectra of the product from the I10H and coronaridine assay (bottom; G). Multiple reaction monitoring of the assay with I10H and coronaridine (H) showing the production of 10-hydroxycoronaridine under standard reaction conditions (E). The unidentified peaks in B and E are products of endogenous yeast enzymes present in empty vector and I10H microsomes.




Figure 4: N10OMT 10-O-methylates noribogaine or 10-hydroxycoronaridine to form ibogaine or voacangine, respectively. HPLC-MS chromatograms and MS/MS spectra of standards and products from enzyme assays with N10OMT and noribogaine or 10-hydroxycoronaridine. HPLC-CID chromatogram of ibogaine standard (A). HPLC-CID chromatogram of reaction product from the N10OMT and noribogaine assay that co-elutes with authentic ibogaine (B). MS/MS spectra of ibogaine (top; C) and mirrored MS/MS spectra of the prod7uct from the N10OMT and noribogaine assay (bottom; C). Multiple reaction monitoring of the assay with N10OMT and noribogaine (D) showing the production of ibogaine under standard reaction conditions (A). HPLC-CID chromatogram of 10-hydroxycoronaridine (E). HPLC-CID chromatogram of reaction product from N10OMT and 10-hydroxycoronaridine assay that co-elutes with voacangine (F). MS/MS spectra of voacangine (top; G) and mirrored MS/MS spectra of the product from the N10OMT and 10-hydroxycoronaridine assay (bottom; G). Multiple reaction monitoring of the assay with N10OMT and 10-hydroxycoronaridine (H) showing the production of voacangine under standard reaction conditions (E).




Figure 5: I10H and N10OMT work in a stepwise fashion to make ibogaine. HPLC-MS chromatograms and MS/MS spectra of standards and products from enzyme assays with I10H and N10OMT and ibogamine. HPLC-CID chromatogram of noribogaine standard (A). HPLC-CID chromatogram of reaction product 1 from the I10H and N10OMT and ibogamine assay that co-elutes with authentic noribogaine (B). MS/MS spectra of noribogaine (top; C) and mirrored MS/MS spectra of product 1 from the I10H and N10OMT and ibogamine assay (bottom; C). Multiple reaction monitoring of the assay with I10H and N10OMT and ibogamine (D) showing the production of noribogaine under standard reaction conditions (A). HPLC-CID chromatogram of ibogaine (E). HPLC-CID chromatogram of reaction product 2 from the I10H and N10OMT and ibogamine assay that co-elutes with ibogaine (F). MS/MS spectra of ibogaine (top; G) and mirrored MS/MS spectra of product 2 from the I10H and N10OMT and ibogamine assay (bottom; G). Multiple reaction monitoring of the assay with I10H and N10OMT and ibogamine (H) showing the production of ibogaine under standard reaction conditions (E).




Figure 6: Relative activity of I10H and N10OMT with different MIAs. Values represent the mean percent maximum activity \pm S.E. of three independent replicates for each compound compared with the substrate showing the highest turnover, which was set to 100%. Trace activity indicates less than 1% turnover.




Figure 7: Steady-state enzyme kinetics of recombinant I10H (A) and N10OMT (B) using ibogamine and noribogaine, respectively, as substrates. Incubation time (25 min) and protein concentration (50 μ g, N10OMT) were optimized prior to kinetic analyses. Values represent the mean product formation (pmol s⁻¹, I10H or pmol s⁻¹ mg⁻¹, N10OMT) \pm S.D. of three independent measurements. Maximum velocity (V_{max}) and the concentration of substrate which permits the enzyme to achieve half Vmax (K_m), catalytic rate (k_{cat}), and catalytic efficiency (k_{cat}/K_m) were determined based on Michaelis Menten kinetics. pH optima of I10H (C) and 10OMT (D). I10H activity was determined for the conversion of ibogamine to noribogaine. N10OMT activity is based on the conversion of noribogaine to ibogaine. (C) The overall pH optimum of oxidation (I10H) and methylation (N10OMT) is indicated by the yellow highlight. Values represent the mean \pm S.D. of three independent measurements




Figure 8: Relative transcripts abundance of I10H and N10OMT in *Tabernanthe iboga* plant organs. Real-time quantitative PCR was used to quantify the relative transcript abundance in root, stem, 1^{st} True Leaf and Young Leaf and cotyledon of iboga seedlings. Data were calculated in excel using $2^{-\Delta Ct}$ and expressed as the mean with S.D. Each data point is indicated with a gray, gold or orange marker. Three biological replicates and three technical replicates were analyzed for each gene using the reference gene: N2227-like family protein, N2227. Efficiencies for all primer sets were approximately equal and always >90%. Values with the same letter are not significantly different (ANOVA with Tukey PHT, p > 0.05).




Figure 9: Relative alkaloid concentration of selected MIAs from organs of *Tabernanthe iboga*. (A) Relative quantity of all reported alkaloids in each tissue. (B) Relative quantity of individual alkaloids in each tissue. Values represent the mean of three biological replicates \pm S.D. Values with the same letters are not significantly different (p < 0.05) using a One-way ANOVA with Tukey PHT (n=3).

Cytochrome P450 and O-methyltransferase catalyse the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga Scott C. Farrow, Mohamed Kamileen, Jessica Meades, Belinda Ameyaw, Youli Xiao and

Sarah O'Connor

J. Biol. Chem. published online July 20, 2018

Access the most updated version of this article at doi: 10.1074/jbc.RA118.004060

Alerts:

- · When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supporting Information

Cytochrome P450 and *O*-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from *Tabernanthe iboga*

Scott C. Farrow, Mohamed O. Kamileen, Jessica Meades, Belinda Ameyaw, Youli Xiao, Sarah E. O'Connor

Table of Contents:

Table S1. Primers used for gene amplification and colony PCR.

Table S2. Primers used for RT-qPCR.

Table S3. NMR spectra of Coronaridine.

Figure S1. Amino acid sequence alignment of I10H with characterized and uncharacterized P450s.

Figure S2. Amino acid sequence alignment of N10OMT with characterized and uncharacterized OMTs.

Figure S3. Phylogenetic trees of I10H and N10OMT.

Figure S4. SDS-PAGE of recombinant OMTs produced in Escherichia coli.

Table S1: Primers used for Full-length Gene amplification and colony PCR

| Gene | Strand | In-Fusion Site | Primer Sequence (5'-3') |
|----------|---------|-----------------------------|------------------------------|
| I10H | Forward | ACCCTCACTAAAGGGCGGCCGCAACC | ATGGAGCTGATCGTCTCCTTC |
| I10H | Reverse | GTCATCCTTGTAATCCATCGATAC | TGCTTCATCCATCATTACC |
| P450-2 | Forward | ACCCTCACTAAAGGGCGGCCGCAACC | ATGGAGTTAGTCACTGCC |
| P450-2 | Reverse | GTCATCCTTGTAATCCATCGATAC | CACAGAAGAATGACTATAAGGAATTG |
| P450-3 | Forward | ACCCTCACTAAAGGGCGGCCGCAACC | GAGCTCATCTTCTTTGTCTG |
| P450-3 | Reverse | GTCATCCTTGTAATCCATCGATAC | TTGTAGATAAGAACGGGAGTG |
| P450-4 | Forward | ACCCTCACTAAAGGGCGGCCGCAACC | ATGGAGCTCATCTTTCTCTTCTG |
| P450-4 | Reverse | GTCATCCTTGTAATCCATCGATAC | GATCGCTTTTTCAAAGAAGAAC |
| P450-5 | Forward | ACCCTCACTAAAGGGCGGCCGCAACC | ATGGAGTTCATTCTTTTCCTTTGCATTC |
| P450-5 | Reverse | GTCATCCTTGTAATCCATCGATAC | CTCCAGTTTTAGGAAAGAACC |
| N10OMT | Forward | AAGTTCTGTTTCAGGGC | CCGGACGCGAAATCTGCCGAAC |
| N10OMT | Reverse | ATGGTCTAGAAAGCTTTA | AGGATACACTTCAATGAGACTCC |
| OMT-2 | Forward | AAGTTCTGTTTCAGGGC | CCGGCAATGGTTGAGAAATCTGC |
| OMT-2 | Reverse | ATGGTCTAGAAAGCTTTA | AGGATAGACCTCAATGAGAC |
| OMT-3 | Forward | AAGTTCTGTTTCAGGGC | CCGGGAGAAGCCCAGGCTCAG |
| OMT-3 | Reverse | ATGGTCTAGAAAGCTTTA | AGGGTAGGCTTCAATGACAG |
| OMT-4 | Forward | AAGTTCTGTTTCAGGGC | CCGAGTGTAGCTTTGAATGGTG |
| OMT-4 | Reverse | ATGGTCTAGAAAGCTTTA | ATAATAAACCTCAATAAGAGATCTC |
| OMT-5 | Forward | AAGTTCTGTTTCAGGGC | CCGGCAGGAGAAGAGGAAGCTTG |
| OMT-5 | Reverse | ATGGTCTAGAAAGCTTTA | TTTAAGCAATTCCATAATCCAACTGTTG |
| OMT-6 | Forward | AAGTTCTGTTTCAGGGC | CCGGATTCTTCCCCCACAATCC |
| OMT-6 | Reverse | ATGGTCTAGAAAGCTTTA | CTTGTAGAACTCCATGATCCAC |
| | | Primers used for Colony PCR | |
| Name | Strand | Vector | Primer Sequence (5'-3') |
| GAL10-F | Forward | pESC-leu2Δ | GGTGGTAATGCCATGTAATATG |
| GAL10-R | Reverse | pESC-leu2Δ | GGCAAGGTAGACAAGCCGACAAC |
| T7-F | Forward | pOPINF | TAATACGACTCACTATAGGG |
| pOPINF-R | Reverse | pOPINF | TAGCCAGAAGTCAGATGCT |

Table S2: Primers used for RT-qPCR

| Gene | Strand | Primer Sequence (5'-3') |
|--------|---------|-------------------------|
| I10H | Forward | AGGCCTCCCTCACTGTGTCCT |
| I10H | Reverse | TGGATGGTCTGTCGGCAAAGA |
| N10OMT | Forward | AAGTGCGCTTACGATGCT |
| N10OMT | Reverse | TCTTCATTCTGGAACCACTCAC |
| N2227 | Forward | GTGAACGTGACCAGTGCTATAA |
| N2227 | Reverse | CAAGCAGGTGGACTCTCTTTAC |

Table S3: NMR spectra of Coronaridine

| Number | This Study | | Reference (22) | | |
|---------------------------------|--|-----------|--------------------------------------|-----------------|--|
| | ¹ H (<i>J</i> /H) | 13 C | ¹ H (<i>J</i> /Hz) | ¹³ C | |
| 2 | - | 138.5 | - | 136.6 | |
| 3 | 2.79 (2H, ddd, 8.5, 1.7, 1.7), 2.94 (2H, ddd, 2.5, 3.7, 8.5) | 54.3 | 2.81 (1H, brd), 2.89-2.92 (1H,m) | 51.6 | |
| 5 | 3.40 (1H, m), 3.00-3.16 (1H, m) | 54.7 | 3.36-3.42 (1H, m), 3.15-3.23 (1H, m) | 53.1 | |
| 6 | 3.00-3.16 (2H, m) | 22.8 | 2.98-3.04 (1H, m), 3.15-3.23 (1H, m) | 22.1 | |
| 7 | - | 110.7 | - | 110.3 | |
| 8 | - | 137.6 | - | 128.8 | |
| 9 | 7.40 (1H, ddd, 7.8, 1.0, 1.0) | 118.7 | 7.47 (1H, brd) | 118.4 | |
| 10 | 7.02 (1H, ddd, 7.6, 7.6, 1.2) | 122.2 | 7.08 (1H, ddd) | 119.2 | |
| 11 | 6.96 (1H, ddd, 7.5, 7.5, 1.1) | 119.5 | 7.14 (1H, ddd) | 121.9 | |
| 12 | 7.24 (1H, ddd, 7.9,1.0, 1.0) | 111.5 | 7.24 (1H, dd) | 110.3 | |
| 13 | - | 129.6 | - | 135.5 | |
| 14 | 1.85 (1H, m) | 29.0 | 1.88 (brs) | 27.4 | |
| 15 | 1.12 (1H, m), 1.76 (1H, m) | 33.2 | 1.13 (1H, ddt), 1.73 (1H, m) | 32.0 | |
| 16 | - | 56.4 | - | 55.1 | |
| 17 | 1.92 (1H, m), 2.72 (1H, ddd, 13.1, 2.1, 2.1) | 37.0 | 1.9 (1H, ddd), 2.58 (1H, dd) | 36.5 | |
| 18 | 0.91 (3H, t, 7.4) | 12.1 | 0.9 (3H,t) | 11.6 | |
| 19 | 1.34-1.49 (1H, m), 1.50-1.62 (1H, m) | 28.0 | 1.4-1.47 (1H, m), 1.53-1.60 (1H, m) | 26.7 | |
| 20 | 1.34-1.49 (1H, m) | 40.1 | 1.32-1.35 (1H, m) | 39.1 | |
| 21 | 3.62 (1H, brs) | 57.9 | 3.56 (1H, brs) | 57.5 | |
| 22 | - | 176.3 | - | 175.7 | |
| CO ₂ CH ₃ | 3.69 (3H, s) | 52.9 | 3.71 (1H, s) | 52.5 | |

| 0: 71A13_camalexin: 71A32_menthofwean_synthase: | | LLVFF | SSFALIIVYFLLFYV | HKRKSSLS | SRKRPPPSPLRLFVIGHFHLI | GALSHRSF7911 |
|--|--|---|--|--|--|--|
| 71211 psoralen synthase: | | NFQYLYFF | | YKUT.2KKT | PLENLPPSFPQYFIIGNLHQI | GPDISTSI |
| 712j4_angelicin_synthase: 71D12_tabersonine_hydroxylase: | Ж2Р | YYPL | YLAFLLFCFIL | SKTTKKFGQN | SQYSNHDELPFGFFQIFILGNAHQLS- | GGRTRRILRDLI |
| 450_3: | MLFQSLME1 | IFFV | AVFLPPCSMV | INTAKKS | KPVKLPPGPKPLPIIGNIHQLS- SPMKLPPGPRPLPIIGNLHQVS- | GPLLERILADL |
| 450_3: 450_5: 108: | | | CILLECLIL | | | GGPIEHVLRDL |
| 10H: 450 2: | NEL | IVSF | FAFLIFCLIS | VKLSTKSKA | DKLKLPPGPRQLPIIGNMHQML- | GGLPSCVLRDL |
| 36312: | | | AYPLIFVILG-ALSWWI | IPIISPLX | | GALPERTL |
| SAZ6_Cr_Iridoid_oxidase: OAl_berbamunine_synthase: OG2_corytuberine_synthase: | XXY | | SISLVALLYFLL | FXP | KHTMLPPSPPAMPIVGHLPDLIS | X-NSPPFLDYMSNI |
| OF1_hyoscyamine_synthase: | | QIALF | SLIPVILVFILL | IRCVISSR | KKLPLPFGFFFMFIIGHLFYL | N-TEVPLRITLANG GNKPRVSLAKLI |
| 1815_camalexin: 181: | XSV | FLCFL | VL1PLILIFLNV | EMIVIRAR | SKYKLPPGPKKLPIIGNLHQR KFKNLPPGPPSLPIIGNLHHL | |
| 128: | X7T | | FYLSLIISLF-FLIITL | XVFFN798 | KPKNIPPGPOCI.PIIGNI.HOL | XOPI.RRTP |
| 2_REPI_morphine: 2Y1_noscapine: | KAYLMI | -KRSIYLFFDQP | TSSVVALLLALVSILTAVGTLILAFLLTL | SPVIIY-YECKKRGLRENT | PASSTKTAVLSHOROOSCALPISGLLHIFMN RTAITTIPLPEASGAMFVIGHLLLFMN | ENDINEVILGENG |
| 2X1_noscapine: 2X2_noscapine: | WEIF | IKLPFIQP | IPFSIILVTT-VSIVLL | YSVFFW-VTDKKK | KRKKAPNAAGAMPLIGHLRLLMN CKIAAPKASGAMPFIGHLKLFMK | |
| 982_canalewin: 7A3: | WATERSSOLTTTATE | TSSFSTLYLL | stlqafyaitlynll | XKLMTDPNK | KKPSLPPGPTGNPIIGHIPTMLK | SRPVFRNL831) |
| 921_canadine_synthase: | XEX | MPLLV | CATVAIVFATTTIIRIL | FSSSSL | PONKWPSGPRKLPIIGNLNQLG- | DDVLEVALAXL |
| 1922_stylopine_synthase: | 22% | -LNOCHYPWIL | TATATTLLISIFL | xxsssi | STMEWPKGPKKLFIIGNLHOLG- | GEAFSVVLANL |
| 1935_cheilanthifoline_synthase: 1981_Salutaridine_synthase: PAl_secologanin_synthase: | WAFINI | EGNOFHMI | ZCTVIIVFALVKFNVPCSFFLLALIKFL | FSKISFYQSA | NTTEWPAGPXTLFIIGNLHQLGG | GVFLQVALANL M-TKEALSKFMALTHDIFFRVQFHIYSC |
| 21219- | MEI | VI.KI.T | | CMRIFNHVHI RPRK | LEKYLRNQGFNGNSYRLFFGDVKEMIV SDODYPKVFEAKGSIOAV | M-LERIESEPINI, YODI I PRI I PLNOKI |
| 7A4_ABA: | KAE | INFL | LEKLGEEKRRAELSARIASGAFTVRKSSFPSTVKWGLSK | VRVIVSKKKKN | SRGKL PPGSMGWPYLGETLOLY- | scnpnvff78K |
| 16A52v2: 10A1_sterol_desaturase: | NELF | SVSIF | slfylfislsfhflfaslapylisa-fllfll | YKSKPSSS | GGFPLPPGKTGMPIIGESYEFLS KKRNIPGPFFVPPIIGNAVALVR | TGWKGYPEKFIFDR DPTSFWDKGSST |
| 620: | | | STALMILSA-ITAYFL | X17FIS | RCLKGPRVWPILGSLPGLIE | NCERMEDWISDNLRAC |
| : 1213_canalexin: | -LNLLHFGRVPILVVSSGER | AQEVL-KTEDHKFANRFRSK-AVEGLMN | nslgvtfaqygdyltklaqiytlell-sqkkvasfyscfe ggrdvvtafyggyhrqxksvcilnll-tnkvvesfekvae | DEVNAMIEKLEKASSS | SSSENLSELFITLPSDVTSRVALGR | XKSEDETARDLKKRVRQII |
| 1232_menthofuran_synthase: 1251_psoralen_synthase: | -LMFLKFGTVPVLVVSSADA | AREAL-KTHOLVFADRFYSS-VANKIFY | | EEVDLLVQNLENSH | SKVANLTELLIEVTGNVVCRVSVG- | SGDKVDSYKILILEIN |
| | -IMOLOLGRIPVIAVARIEL | TREVI-KIRDWVPSORPITS-LIDKLCY | KCRDVL PRRYSEYMROURSTOUTOLL-SNSRVHSPHNIRE | REVALLIONIENSA | REVINIGENTIALTRNVVCRVSVGS | EVISCHECKI.YORI.I.EVI |
| ID12_tabersonine_hydroxylase: ID13_gelsenium_sempervirens: | -LMHLKLGEVSYIVLSSAEV | AKEVM-NOHOILPSSRPELL-SVRIIDY | DFSDMVVSPYGNYWRQLRKISMMELL-SQKSVQSFRSIRE NCTNITFSPYGDYWRQLRKICTVELL-SAKRVQTFRSLRE | EEVLNMIKLVFH-KK | GSVVNLSKMVFSVTYSIIAQAAFGK | RSKYGEEFLVLMEET |
| .50_3: .50_3: | -UNHIGIGEVITIVITSAEA | akevn-qoqovifayrpytl-aakilyy akevy-ktholifaqrpscfeatraisy | NRSDMAFSPYGDYWRQLRKICTVELL-SPKRVQDFRSIRE DFTDIIFSPYGNYWRELRKICTMELL-SPKRVRTFRSIRE | EEVINNIGSISLHK EEVINNIRSISLQE | gsaanlskvifsltysiiaqaafgk gsvvnlsqkifsltycitsraafgk | RIKTQDEFVRVMEDV |
| 150_5: | -TMYTATOPTOTTTMESSEW | AMERICAN PROPERTY AND AMERICAN PROPERTY OF THE PARTY OF T | NETRITERRYCHYMBOTERTEMIELL-CEREUOTEOGIET | PRIT 01 TD 07 01 WF | CERTAL SOMITEST TYCTTARAL FOR | |
| 150_2: 163.12: | -LMHIRIGEVPVVIVSSPEV | AEQFM-KINDIVFAYRPLFL-SSRILNY | DFLDIFASPYSDYWRQLRKICTNELL-SSKRVQSFRSIRD DGTSIVFSPLGDYWRQLRKICTNELL-SFKRVQSFRSIRE GTNGMSFTLYGFRWRNTRKFVVLELL-TRKINSFVQMSK | EEILNLVRSISLXK | GSPINLSRKIFSYSHGVVTRAAFGK | XXXXXQEEFTSLVEES |
| A26_Cr_Iridoid_oxidase: | -IVWLQLGSINTMVVQNAVS | ARELF-KKHOVPFCDRKVPD-TLTAFNF | NQGSLGMNTYGGHNRVLRRLCSMEFL-VNKRMNETTDLRR | RIEDMOVRHIEEDSLASKAGG | GTGAVQLSRFLFLMAFNLVGMLMLSR | DLMDNKDPEGREFFDCHNEI |
| Al_berbamunine_synthase: G2_corytuberine_synthase: | -T.THI.KPCI HESTPLSTERL | AMENT - OTNORNI ROROPI P-CERTERS | TOYSTIMSDSNSYMKKGSKTIMTETF-SOKMIOLOEKNSS | BVLCNIVNFIMTKV | GDMFET.RRMT.PGC3.1MVT.GRVMFRK | TATEEYSDOSDEWGMDKT.TRGMT |
| G2_corytuberine_synthase: F1_hyoscyamine_synthase: | HLMSIRLGGRLVIVASSPMA | TAEVI-KTHORLLSGRFVSH-FMRVEGSYI- | IKYSLVWSDCTDYWKLLRKIVRTEIF-SFKMLQAQSHVRD -RMLATETLEECDENWKKVRSMYQIVLF-SEKAVESQVNIRE NFKDIGNAFFGDEWSLARKLSVVELF-SVKKLOSFKYIIE | KKVMELVKFVASKE | GELVNIKGIAFVTILNILSMSTISM | DLVDFEGKGIGEGMRENIRMY |
| B15_camalexin: E1: | -VFSLWFGSRLVVVVSSASE | FQQCF-TKMDVVLANRPRFL-SGKYIFY | NYTTLGSTSYGEHNRNLRRITALDVL-SNHRINSFSGIRR | DETORLITRIADDSST | NFAEMELSSRLYDWTFNNIMRMISGK | RYYGEDCDTSDLGEASGFRDWVSEL |
| LES: 2_REPI_morphine: | -IFSLWFGSRLVVVVSSLTI | AGECF-TKNDIVLANRPHFL-TGKYIGY | NNTTVAQSPYGDHWRNLRRILSIEIL-SSHRLMSFLEIRR | DEINRLIGKLAGKSYN | PERSONAL PROPERTY OF THE PROPERTY OF THE ORDER | OCCU |
| Yl noscapine: | -IFSLREGRHRTLVVSSWEM | VERCETGINDELFANRPASI-AVELMEY | DTESYGFAPYGKYNRELRKISTHKLL-SWOOLEKFKHLRI | SEVENSFERLEELCSNNKCGG- | -DTTYVASLVEMDDWFAYLTFNVIGRIVSGF | OSNAVAGATNSOEKYKLAIDEVI |
| XX_noscapine: | -VFTLRIGHQAILVVSNWEW | | OTTSSGFAPYGPYNRELRKIN/OOLL-SKQSLESWKKLKI: DINSVVFSPYGTYNRENRKIL/OOLLISNORSEALKNLKT | KEIDNSFYKLNDLCNNDVSG | gotkvandenladnofnilaritfgy | QSGG-GDAPGASTTSKNVERYKKTLDENI |
| 32 canalexin: | EIRCVKLGNTHVITVTCFKI -IFTLKKGTRTWIILTDAKL | are il-koodalfasrplty-aokilsn vheam-iokgatyatrppen-ptrtifs | GYKTCVITFFGDOFKENEKVNETELV-CFARHENLEOKES -ENKFTVNAATYGFVHKSLERENEVONKL-SSTRLKEFRSVED SWHTISTSDAGSFWONVEKGLOSGAN-GFLNVAAONOYOK | EENDHLTANVYNDVKNEK KANDKLINRLKDEAEK | sgsvdfrfntrhycgnaikklmfgt nngvvnvlkdarfavfcilvamcfgl | rtfskntap-dggptvedvenkeanfea: Endeetveridgvkksv: |
| 7A3: 19A1_canadine_synthase: 19A2_stulenine_sunthase: | -VMTINIGSWRPVIVISDIEK | AMEVI-VNKSADYGARDMFE-ITKIASA | SWHTISTSDAGSFWONVRKGLOSGAM-GFLNVAAONOYOE DWKTISTSDSGPHWTWLRKGLONVAL-SPHNLAAOFOFOE | RINKRLIKAMSDEAAN | NNGIVKPLDHIKKNTVRLLTRLIFGG | AFDDNKFIESMHYEIEDI: |
| SA2_stylopine_synthase: SA5_cheilanthifoline_synthase: | -VMTIWVGAWRPMIVISDIDK | AWEVL-VNKSSDYAGRDFPE-ITKIISA | NWKNISCSDSGPFWQMLRKGLQGGAL-APLNVISQYQLQE | RIMKNLITSMQEKASK | NNGILKPLDYLKEETIRLLSRLIFGQ | SFNDENFVKGVHLALDDLY |
| 1981_Salutaridine_synthase: PAl_secologanin_synthase: | -NFLYWDGVRPELVISEPEL | IKEVL-KNSEKTFPKRKPTIFINKLLGD | MGKNIADODSGPFWHMLKKGLQS-CI-NPSNVMSLSRLQE GLVTVEGEKWVKQRKLANNVFHGESLKOMRPAII: | RSVETHLKKNKGQV | HNGIIKPLDHAKEASMRLLSRVIFGH GKEIEVFHEFKLLTSEVISRTAFGS | SYLEGEKIFENLNKL |
| 12219: | -NSFLWLGPKPMUHIMNPDH | INDVL-SEFYOFOKPRHNPLTKLLAT | CVADARGORNAKHRKLINPAFHIRKLKNMLPAIY | LASSEIVTKHEEMVST | KOOFELDVLPYLETLTSDVISRTAFQS | SYEEGRKIFOLORED |
| 7A4_ABA: 16A52+2: | -IFKTRILGYPCVMLASPEA | ARFVL-VIHAHMFKPTYPRS-KEKLIGP | KGLIPADGEIMRRRRRAIVPALHQXYVAAMISLFG SALFFRQGDYBSHIRKLVQSSFYPETIRKLIPDIE STGTSSKEEAIKGRXMLPNFFXPEALGRYIGIND | HIALSSLOSMAN | MPIVSTYQEMKKFAFDVGILAIFGK | LESSYKEILKHY |
| 16A3292; 10A1_sterol_desaturase; 5A8; | -SANYLIGKFIVYIRDTEL CICAIPFLAKKQGLVIVICDFRK | SKOIFSNVRPOAFKLIGKPF-GKKLFGD LENIL-KNRFONYPKGPTHOAVFK | | CIAANSFESONESTSG LVILRHLRQNEGSTSG RAIKLRFLPILENARL | gsryvslagivreinietsgtvfvgp gsepidlgdiliritfdnicgitfgk | YLDKEAKNRFRTOYNLI DPRTCAPGLPVNTFAVAFDRA: |
| | TPLRLEDLFPSMSIFCRFSKT | LNGIRGLIGEMDDILERIIVEREKAS-EVSK | DANGEROU TANKERUNGUN ACAMERA | | | RVIGY-DVERMERMALCVK |
| lal3_canalexin: | | | | INADIKATIFELILAATLSVADUTRI | MAMVEILROPKSLKKVYEEVRGICKFKK- | |
| | E-FPIGEYVPILAWIDGIRGE | NNKIKEVSRGPSDLMDKVVQEHLE | ASNDKADF-VDILLSIEKDKNSGFQV | ORNDIKFHILDMFIGGTSTTSTLLE | WINTELIRSPKSMKKLQDEIRSTIRPHGS | YIKEK-EVENDKYLKAVIK |
| 1132 menthofuran synthage. | S-FNVGDYVPWLSWINRINGV S-RSIEDFFPLLGWVDWL7GL | DAEVEKVGTKLDGSMEGILRKYRRKK RGKVARAAKGVDTFLEGVLKERLST | ASNDKADF-VDILLSIEKDKHSGFQV | ORNDIKFHILDHFIGGTSTTSTLLE: EDDVIKALIFDHVSAGTDTTFAALE: | WTHTELIRSPKSMKKLQDEIRSTIRPHGS WTWAELIKNPRTLKTLONEVREVSRNKG- | YIKEK-EVENNKYLKAVIK |
| LA32_menthofuran_synthase: LA31_psoralen_synthase: LA34_angelicin_synthase: | S-FNVGDYVPWLSWINRINGV S-RSIEDFFPLLGWVDWLTGL T-YSIGDFIPLLGWVDWLSGS | DAEVEKVGTKLDGSMEGILRKYRRKK RGXVAEAAKGVDTFLEGVLKEHLST KAKVEKTAKEVDAFLEGALRDHIKTM-ASN- | | DANDIKPHILDHFIGGTSTTSTLLE EDDVIKALIFDMYSAGTDTTFAALE DNECIKSLINDMLGAGTETISTALE DEECIKALYHDMILGGTETTSTLE DEECIKALYHDMILGGTETTSTTLE | WINTELIRSPKSNKKLODEIRSTIRPHGS WINAELIKNPRILKILONEVREVSRNKG- WILAALIKNPDAMFKLONEVREIGKGKS- WIVAALIKNPDVMFKLOKEVREIGKGKS- | YIKEK-EVENNOKYLKAVIKYIKEK-EVENNOKYLKAVIKKISEA-DLVKNOYIGAVNOKKISEA-DLVKNOYIKAVNOK |
| 1332 menthofuran_synthase: 1371 menthofuran_synthase: 1372 menthofus menthose: 1372 menthofus menthose: 1373 menthose: 1373 menthose: 1373 menthose: 1373 menthose: | S-FNVGDYVPWLSWINRINGV S-RSIEDFFPLLGWVDWLTGL T-YSIGDFIPLLGWVDWLSGS | DAEVEKVGTKLDGSMEGILRKYRRKK RGXVAEAAKGVDTFLEGVLKEHLST KAKVEKTAKEVDAFLEGALRDHIKTM-ASN- | | DANDIKPHILDHFIGGTSTTSTLLE EDDVIKALIFDMYSAGTDTTFAALE DNECIKSLINDMLGAGTETISTALE DEECIKALYHDMILGGTETTSTLE DEECIKALYHDMILGGTETTSTTLE | WINTELIRSPKSNKKLODEIRSTIRPHGS WINAELIKNPRILKILONEVREVSRNKG- WILAALIKNPDAMFKLONEVREIGKGKS- WIVAALIKNPDVMFKLOKEVREIGKGKS- | YIKEK-EVENDKYLKAVIKIKISEA-DLVKMYLGAVMKIKISEV-DLVKMYLGAVMKI |
| 1332 menthofuran_synthase: 1371 menthofuran_synthase: 1372 menthofus menthose: 1372 menthofus menthose: 1373 menthose: 1373 menthose: 1373 menthose: 1373 menthose: | S-PNYODYVPHUS-WINKINGVY S-RSIEDFFPLLG-WYDMLTGLI T-WSIGDFIPLLG-WYDMLSGS: E-PNIADMFPSLK-FLQLISTS: G-FSIADLYPSIK-LLEVISGGI: G-FSIADLYPSIK-LVEVISGGI: G-FNIADMFPSVK-WLKYLEGG | DAEVERVOTKLDOSMEDILRYPREKE RAKVAEAARGVUDTFLEGVLKERLST KAKVEKTAKEVDAFLEGALRORIKTM-ASN- KYKIEKIHKOFDVI VETILKGHKEKI-NKPI RORLEKIHKKOTDI LOONI LOERKEKKA-NRLE ROKLOKAHKKIDRINGSTILNEHKEES-RKS- ERKLOIVAKOVEE VONI LNEHKEGG-NKE | ASNEKADF-VOILLEIKE- KNSETYV VOODETN-VOILLEIKE- KNSETYV TOSKTNOF-VSILLEIGE ADASSSM KOSANOF-ISILLEIGE ADASSSM KOSANOF-ISILLE | QANDIKHMILDOFIGGTSTTSTLEE EDDVIKALIFOMVSAGTDTTFALEE EDDVIKALIFOMVSAGTDTTFALEE DEECIKALIVEOMILGGTETTSTTLEE DEECIKALIVEOMILGGTETTSTTLEE IGKNIKALIFNIFSAGTETSSTTVOM IGDNIKAVISOTYAAGGESSATTATI SCONIKAVISOTYAAGGESSATTATI EDDNIKAVITOTYSAGGETSATTSTI EDDNIKAVITOTYSAGGETSATTSTI EDDNIKAVITOTYSAGGETSATTSTI | WINTELIRS PKSNKKKLOEIRSTIR.—PHOS WITHOLELIKS PRIKKTLONEVREVSR.—NKG- WILALLIKS PDANFYKLOMEVREIGK.—CKS- HIVAALIKS POWNFKLOMEVREIGK.—CKS- HIVAALIKS POWNFKLOMEVREYN.—EEG- WITHELS HIKS PLOKKAGE EVRAVYN.—EEG- WITHELS HIKS POWNFAGGE VRAVYN.—CKG- WITHELS WITH HAS POWNFAGGE VRAVYN.—CKG- WITHELS WITHER HER WITHER WIT | YIKER-PURNOKYLKAVIK |
| 1332_menthofuran_synthase: 13/1_pso-slam_synthase: 13/4_angelicin_synthase: 13/4_angelicin_synthase: 13/2_tabesconine_bydroxylase: 13/2_disenium_sempervirens: 150_3: 150_3: 150_3: 150_6: | S-FNYGOYVENUS-WINGHOW S-RSIEDFFPLLG-WYDMLTGG: T-PSIGOFFPLLG-WYDMLTGG: E-PNIADMFPSLKFLGVISGG: G-FSIADIYPSIKLVEVISGG: G-FNIADMFPSVKWLRVLSGG: G-FNIADMFPSVKPLGVISGG: G-FNIADMFPSVKPLGVISGG: G-FNIADMFPSVKPLGVISGG: | DADVENOTELDSSEGILENTERKE RENYABRAKUNDTELGULKERIS 5 - HANYERIKES SAMURIKES | ASSISTATO - VOLLETERS - MASSINGV - VOLUMENT - VOLLETERS - SKOTDV - TOSKYNON - VALLETON - ANASSIS - KOSANON - SILLETON - ANASSIS - SEGREKKON - VVLLSTORR - MOTERAP - SEGREKKON - VVLLSTORR - MOTERAP - SERENCE - VVLLSTORR - DOTTON - TO SERENCE - TUTLSTORR - DOTTON - TO SERENCE - DOT | Dendirkilder Locktor to Electric Edulikali Ponyagoth Pales Dencirs Limbelgageti Stales Dencirs Limbelgageti Stales Dencirs Limbelgageti Stales Dencirs Limbelgageti Stales Donikavi Dot Paggeti Stales Tonikavi Pot Paggeti Stales | HITHELLIS PKRIMIKLOGE IRSTIRPRO- HITLALLIK PRILKTLONE VREYSRNKO- HITLALLIK PED DAMPKLOGE VREIGKGKS- HITLALLIK PED POMPKLOGE VREYTEGKG- HITMEDHIK PED VLARA GE VREYTEDKG- HITMEDHIK PED VLARA GE VREYTEDKG- KALSELIK PED FLARA GE VREYTEDKG- | - TIRRE-EVENNYIKAVIR GITED-DVDNSFYIKAVSK KISRA-DUVNSFYIKAVSK KIERY-DUVNSFYIKAVSK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK -NOES-GLHELONGALIK |
| 1312_menthofuran_synthase: 1314_angelicin_synthase: 1314_angelicin_synthase: 1312_tabersonine_bydroxylase: 1312_tabersonine_bydroxylase: 1313_galsemium_sempervirens: 1450_3: 1450_3: 1450_3: 1450_3: | S-ENVGOYVENLS-WINKING S-RSIEDFFILLG-WYDMIAGG T-YSIGDFIFLLG-WYDMIAGG E-FNIADHFSIKFLQLISTG G-FSIADHFSIKLEVISGG G-FSIADHFSIKLEVISGG G-FNIADFFSIKPLGVISGG G-FNIADFFSIKPLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG | DAVVENOTYLDOSIGGILENYRRKK ROKVARARKYDDAFEDOLARIST RAKVERKENKOFDUTUTILKORRKKI-INK ROKKIEKINKOFDUTUTILKORRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDIDIRKKI-INK ROKLORAKIEKINDIDIRKKI-INK ROKKIEKINDIDIRKKI-INK | ### ################################## | DNOINEMILOM COTSTSTLE EDVIRALTON/SAGTDTTSALE DNECKSLIMMICACTTTSTLE DECKRALT/MONILOCTETSTLE DECKRALT/MONILOCTETSTLE DECKRALT/MONILOCTETSTLE DECKRALT/SOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DECKRALTSOLVADORS | THE THE PROJECT OF TH | TIME FURNITARY IN THE STATE OF |
| AA32_menthofusan_synthase: 1A3(_angulicin_synthase: 1A3(_angulicin_synthase: 1A3(_angulicin_synthase: 1D32_gulicin_synthase: 1D32_gulicin | S-ENVGOYVENLS-WINKING S-RSIEDFFILLG-WYDMIAGG T-YSIGDFIFLLG-WYDMIAGG E-FNIADHFSIKFLQLISTG G-FSIADHFSIKLEVISGG G-FSIADHFSIKLEVISGG G-FNIADFFSIKPLGVISGG G-FNIADFFSIKPLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG G-FNIADFFSIKFLGVISGG | DAVVENOTYLDOSIGGILENYRRKK ROKVARARKYDDAFEDOLARIST RAKVERKENKOFDUTUTILKORRKKI-INK ROKKIEKINKOFDUTUTILKORRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDILDIRKKI-INK ROKLORAKIEKINDIDIRKKI-INK ROKLORAKIEKINDIDIRKKI-INK ROKKIEKINDIDIRKKI-INK | ### ################################## | DNOINEMILOM COTSTSTLE EDVIRALTON/SAGTDTTSALE DNECKSLIMMICACTTTSTLE DECKRALT/MONILOCTETSTLE DECKRALT/MONILOCTETSTLE DECKRALT/MONILOCTETSTLE DECKRALT/SOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DONIKALTSOLVADORS DECKRALTSOLVADORS | THE THE PROJECT OF TH | TIME FURNITARY IN THE STATE OF |
| 1332_manthofusan_synthase: 134_angularin_synthase: 134_angularin_synthase: 134_angularin_synthase: 135_gularin_shydrosylase: 135_gularin_shydrosylase: 135_gularin_shydrosylase: 135_gularin_shydrosylase: 135_gularin_shydrosylase: 135_gularin_shydrosylase: 135_gularin_shydrose: 135_gularin_shydrose: 135_gularin_shydrose: 135_gularin_shydrose: | S-TRIVODY/FRIS-MIDRINOV S-RESIDENT/S-MIDRINOV T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIMATE TO THE TOTAL T-YSIGOFI PLIMA | DARVENOTTKI DESKOLILENTRAKK RENVERLAKUTOTKI DESKOLILENT ADN RENVERLAKUTOTKI DESKOLIKTYA ADN RENVERLAKUTOTKI DESKOLIKTYA ADN RENVERLAKUTOTKI DESKOLIKTYA DE RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA | ### MINISTRA TOLLETTE - SHARPON - TOLLETTE - SHARPO | MANDERHILDMY COTSTSTLE ENOVERLIE FOR SACTOTTABLE ENOVER SACTOTTABLE ENOVERSE ENOVER SACTOTTABLE ENOVER SACTOTTABL | WITTELLA SPANISKA COETASTA - PASSI WITTELLA SPANISKA COETASTA - PASSI WITTELLA SPANISKA COETASTA - PASSI WITTELLA SPANISKA COETASTA - CHARLES WITTELLA SPANISKA COETASTA - CHARLES WITTELLA SPANISKA COETASTA - CHARLES WITTELS SPANISKA COETASTA COETASTA COETASTA - CHARLES WITTELS SPANISKA COETASTA COET | TIESE - PURBOYLANTE GITED - DOUGHETHANNE HI SEA - DOUGHETHANNE HI SEA - DOUGHETHANNE FORET- SAMENICANTE FORET- SAMENICANT |
| 1317_menthefusen_synthase; 13/_sepain_synthase; 13/_sepain_synthase; 13/_sepain_synthase; 13/_sepain_synthase; 101_gelsenium_sempervisens; 101_gelsenium_sempervisens; 101_gelsenium_sempervisens; 101_sepain_sempervisens; 101_sempervisens; | S-TRIVODY/FRIS-MIDRINOV S-RESIDENT/S-MIDRINOV T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIG-MYVORIGAD T-YSIGOFI PLIMATE TO THE TOTAL T-YSIGOFI PLIMA | DARVENOTTKI DESKOLILENTRAKK RENVERLAKUTOTKI DESKOLILENT ADN RENVERLAKUTOTKI DESKOLIKTYA ADN RENVERLAKUTOTKI DESKOLIKTYA ADN RENVERLAKUTOTKI DESKOLIKTYA DE RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA RENVERLATUROTVE DESKOLIKTYA DESKOLIKTYA | ### MINISTRA TOLLETTE - SHARPON - TOLLETTE - SHARPO | MANDERHILDMY COTSTSTLE ENOVERLIE FOR SACTOTTABLE ENOVER SACTOTTABLE ENOVERSE ENOVER SACTOTTABLE ENOVER SACTOTTABL | WITTELLA SPANISKA COETASTA - PASSI WITTELLA SPANISKA COETASTA - PASSI WITTELLA SPANISKA COETASTA - PASSI WITTELLA SPANISKA COETASTA - CHARLES WITTELLA SPANISKA COETASTA - CHARLES WITTELLA SPANISKA COETASTA - CHARLES WITTELS SPANISKA COETASTA COETASTA COETASTA - CHARLES WITTELS SPANISKA COETASTA COET | TIESE - PURBOYLANTE GITED - DOUGHETHANNE HI SEA - DOUGHETHANNE HI SEA - DOUGHETHANNE FORET- SAMENICANTE FORET- SAMENICANT |
| 1337_menthefusen_synthase: 135_ments_nynthase: | S-PROMOTYPELS-MINELSON -SHEEPERS-MINELSON -YESSERFELD-MINELSON -YESSERFELD-MINELSON -YESSERFELD-MINELSON -YESSERFELD-YESS | DALVENOVELLOSSIGGI INVESSIGGI ANTORIALATORIA PROVINCERIA: ANTORIALATORIA INCLASSICA ELITO-LIS- ANTORIALATORIA INCLASSICA ELITO-LIS- ANTORIALATORIA INCLASSICA ELITO-LIS- ANTORIALATORIA INCLASSICA ANTORIALATORIA ANTOR | ABBORAN-VOLLES SENTON- VOLUMENT VOLLES SENTON- ANA COCCAMANO COLUMENT VOLLES SENTON- ANA COCCAMANO COLUMENT VOLLES SENTON- VOLUMENT VOL | NAME OF THE OWN TO STATE THE TELL OF THE OWN THE T | WITHTELD REPRINDING COLOR TO THE ALL TO PROVIDE THE | TIME - EVENOUT MANTE STEED - DEVINENT LANDING HE SEA - EVENOUT LANDING FURTH - LORGERY LANDING FURTH - LORGERY LANDING FURTH - LORGERY LANDING FURTH - EVENOUT LANDIN |
| 1332_mentfoream_synthase 1341_mentlem_synthase 1311_timentlem_synthase 1311_timentlem_synthase 1311_timentlem_synthase 1311_timentlem_synthase 1301_3 1301_timentlem_synthase 1301_1 1301_timentlem_synthase 1301_timentlem_sy | S-PROMYPHIS-MINHINGHAM S-RESERVED-MONICOLI T-SIGNIFICATION T-S | DARTYPOTICOS DESCRIPTION DE L'ANTENDAME REFORMALIANT DE L'ANTENDAME | ABBRIGATO-TOLLERS - SERIESTO- TOURS - TOLLERS - SERIESTO- TOURS - TOLLERS - SERIESTO- | NAME OF PROPERTY AND ADMINISTRATION OF PROPERTY ADMINISTRATION OF PR | WHETELIA PRINSKA, QUERATIA - PRIS WHATELIA PRINSKA, QUERATIA - PRIS WHALLE PRINSKA, QUERATIA - PRIS WHALLE PRISA PRIS WHALLE PRIS WHATELIA PRI | TIES - PUBBYLAND IN TIES - TURBYLAND IN TIES - TURBYLAND IN TIES - TURBYLAND IN TURBYLAND IN TURBS - TURBS - TURBYLAND IN TURBS - TURBS - TURBYLAND IN TURBS - TU |
| 1312_monia_pythase 131_monia_pythase 131_monia_pythase 131_monia_pythase 131_monia_pythase 130_3 | S-PRODUPTES-MINISTED PRESENTATION PRESENTATI | DATE TO THE CONTROL OF THE CONTROL ON THE CONTROL OF THE CONTROL ON THE CONTROL OF THE CONTROL O | ABBORANT-VOLLENES- DESERTOR- POSSESSI POLLENES- DESERTOR- POSSESSI POLLENES- DESERTOR- | NO DIRECTION OF CONTROLL ON TO CONTROLL ON THE | THE TAX PROPRIESE OF TAX PROPRIESE OF THE TAX PROPR | TIES - FURBINIZATION CONTROL OF THE STATE OF |
| 133_mentatorous_probases (b)_precedus_probases 101_tableses 101_table | S-PROGUTYPHIS-MINHINGOUS PARRIED STATEMENT OF SERVICE PROGUES OF SERVI | TARTETUTION CONTROLLARISMONIA | ### ### ### ### ### ### ### ### ### ## | NAME OF A THE PROPERTY OF A TH | THE CONTROL OF THE CO | THE PUBBILAND AND AND AND AND AND AND AND AND AND |
| 133_menthofwan, probases [10]_mentlan, probases [11]_mentlan, probases [12]_mentlan, probases [13]_mentlan, probases [13]_mentlan, probases [14]_mentlan, probases [15]_mentlan, probases [15] | S-PRODUTYPELS-NEXELEDY NO. S-PRODUTYPELS-NEXELEDY NO. S-PRODUTYPEL | SACREMONICA DE LA CONTRACTA DEL CONTRACTA DE LA CONTRACTA DE L | ### ################################## | NAME OF THE PARTY | THE CONTROL OF THE CO | THESE PROSECULATION THE |
| 1337_menthof-wass_problems 132_menthof-wass_problems 132_tablems_problems 132_tablems_problem | 5-PRODE/PRIME PRODE/PRIME PROD | AMERICAN CONTROLLAR CO | ABBOARD-VOLLEIBES - SHEETEN- | NORSENTAL ORGANIZATION OF STREET STATES OF STA | WITCH LAND AND CONTROL THE TOTAL CONTROL LAND AND CONTROL | THESE PURBOYLAND IN THE PURBOYL |
| 133_menthofwan, yenthasi 132_menthofwan, yenthasi 133_menthofwan, yenthofwan, yenth | 5-PRODE/PRISE - PRODE/PRISE - | SACREMONING SERVICE SE | ABBOARD-FOILLIBER - SERIESTS - | | THE CONTROL OF THE CO | THESE PERSONALATION THESE PERSONALATION THE PERSONALATION THE THE PERSONALATION THE |
| 133_mention_synthese 132_telephone_synthese 132_telephone 132 | \$ - PRODUCTION | AMERICAN CONTROLLAR CO | ### ### ### ### ### ### ### ### ### ## | NORTH TO THE TOTAL | THE CONTROL OF THE CO | THESE PURBOUTANCES THE PURBOU |
| 133_manthofwama_pynthase; \[\(\) | \$ - PROVIDENTIAL PROVIDENTI | AMERICAN CONTROLLAR CO | ABBOARD-FOILIBLE - SERIES - VOICE - SERIES - VOICE - SERIES - VOICE - SERIES - SERIE | | THE CONTROL OF THE CO | THESE PERSON LANCHINGS THE PERSON LANCH TO THE |
| 133_manthofwama_pynthase; \[\(\) | \$ - PROVIDENTIAL PROVIDENTI | AMERICAN CONTROLLAR CO | ABBOARD-FOILIBLE - SERIES - VOICE - SERIES - VOICE - SERIES - VOICE - SERIES - SERIE | | THE CONTROL OF THE CO | THESE PURSON LAND THE STATE OF |
| 133_menthofwams_synthase | - PROVINCIPIEL - PROGRAMMA - PROVINCIPIEL - PROGRAMMA - PROVINCIPIEL - PROGRAMMA - PROGRAM | THE PROPERTY OF THE PROPERTY O | ABBOARD FOILLIBRE SERVEY SOURCE FOILLIBRE SARRY TO REALEST FOILLIBRE SARRY | | THE CONTROL OF THE CO | THESE PURSONIANT TO THE PROPERTY OF THE PROPER |
| 133_menthofwams_synthase | - PROVINCIPIEL - PROGRAMMA - PROVINCIPIEL - PROGRAMMA - PROVINCIPIEL - PROGRAMMA - PROGRAM | AMERICAN CONTROLLARISAN DEN CONTROLLARISAN DE CO | ### ### ### ### ### ### ### ### ### ## | | THE CONTROL TO THE CO | THESE PURSONIANT TO THE PROPERTY OF THE PROPER |
| 133_mention_synthese | \$-000000000000000000000000000000000000 | AMERICAN CONTROL AND SAME AND | ### ### ### ### ### ### ### ### ### ## | MORPHICA DES GOSTOSTATIONS DE MONTRE DE LA CONTRE DEL CONTRE DE LA CONTRE DEL CONTRE DE LA CONTRE DEL CONTRE DE LA CONTRE | WITCHELS PRINCE CONTROL TO THE CONTR | THESE PURBOTIANTIES THE PURBOTI |
| 133]_menthofwams_synthase | 8-PROCESSIVES PROCESSIVES PROC | DATESTOCIO DE CONTROLO DE CONT | ### ### ### ### ### ### ### ### ### ## | MONOPHIC LONG GOODST STATE LONG TO CONTROL T | THE CLASS PROPRIES OF THE | THESE-PERSONALY IN THE PERSONALY IN THE PERSONALY IN THE PERSONALY IN THE PERSONAL IN THE PERS |
| 133_mentiofvan, yenhasi 135_mentio, yenhasi | - PRODUCTIVIS PROGRAMMA - | SAFETY OF THE STATE OF THE STAT | ### SERVICE OF THE PROPERTY OF | MONEMATIC DOS GOSTOSTICOS DE CONTROLO DE C | WITCHELS PRINCE CONTROL THE TOTAL TOTAL CONTROL TO THE TOTAL CONTROL TO | TITLES - PURBOYLANDE TITLES - PURBOYLANDE HERY - SUVENITURE HERY - SUVENITURE HERY - SUVENITURE FOR - FOR - HERY - SUN - SU |
| 133 _manthofusas_pythase 132 _manthofusas_pythase 132 _table_manthofusas_pythase 133 _table_manthofusas_pythase 134 _table_manthofusas_pythase 135 _table_m | \$-000000000000000000000000000000000000 | AMERICAN CONTROL AND SAME AND | ### ### ### ### ### ### ### ### ### ## | MORPHATICAL ON GOODSTRANGE AND | WITCHELSPANDING COLLEGISTISTS - MAN- CONTROL LOUDING THE CONTROL LOUDING TO THE CONTROL LOUDING THE CONTRO | THESE-PROSPITATION THESE-PROSPITATION HERE - SUPPRISON HERE - SUPPRISON FOR THE SUPPR |
| 133 _manthofusas_pythase 132 _manthofusas_pythase 132 _table_manthofusas_pythase 133 _table_manthofusas_pythase 134 _table_manthofusas_pythase 135 _table_m | \$-000000000000000000000000000000000000 | AMERICAN CONTROL AND SAME AND | ### ### ### ### ### ### ### ### ### ## | MORPHATICAL ON GOODSTRANGE AND | WITCHELSPANDING COLLEGISTISTS - MAN- CONTROL LOUDING THE COLLEGISTS AND THE COLLEGISTS AN | THESE-PROSPITATION THESE-PROSPITATION HERE - SUPPRISON HERE - SUPPRISON FOR THE SUPPR |
| 1333_manthof-seam_synthase 132_manthof-seam_synthase 132_table-seam_synthase 133_table-seam_synthase 1 | \$-000000000000000000000000000000000000 | AMERICAN CONTROLLAR CO | ### ### ### ### ### ### ### ### ### ## | MONEMATIC DOS GOSTOFT STATE OF THE STATE OF | WHITELEASHARDAGOGENETETH-MOST AND | THESE-PERSONALIVE STATES OF THE STATES OF TH |
| 133_menthofwan, yothase 132_menthofwan, yothase 132_tablescan, yothase 132_ | S-PONDERFUL HORSENDE PONDERFUL POND | DATESTOCIO DE CONTROLO DE CONT | ### ### ### ### ### ### ### ### ### ## | MORESTALL DISCOGNISTICATION OF CONTROL OF CO | WITCHELS PROPRIES OF THE TOTAL OF THE TOTAL CONTROL | THESE-PERSONALATION THESE -PERSONALATION THE -PERSO |
| 1333_manthof-wass_puthase 132_manthof-wass_puthase 132_table_manthof-wass_puthase 133_table_manthof-wass_puthase 133_table_m | - PRODUCTIVES - PROGRAMMA - PR | AMERICAN CONTROL OF THE CONTROL OF T | SIRICALP - VOILLIES | MORRANDI GOSTOFF THE MAN TO STANK THE MA | WITCHELS AND | THESE-PROSECULATION THESE- |
| 133_manthofouna_pythase 132_manthofouna_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name_pythase 132_table_name 132_ta | - PRODUCTIVIS - PROGRAMMA - PR | SACRETORISTICATION CONTROLL STORMAN CONT | SERIOLOPY-OLLES ENGINEER SOURCE STATEMENT OF SERIOLOPY SOURCE STATEMENT OLLES SERIOLOPY SOURCE SERIOLOP | MORRANDI DOS GOSTOSTATION DE SECRETARIO MORRANDI SECRETARIO MORRA | WHEN THE PROPERTY OF THE PROPE | TITLE - FURBRITANTIES TITLE - TOTAL THE STATE OF THE STA |
| 1333_manthofouna_pythiass 1332_manthofouna_pythiass 1332_table_na_pythiass 1332_table_na_py | - PROVIDENTIAL - PROV | AMERICAN CONTROLLAR CO | BRIDADI-VOLLEIER BRIDADI-VOLLEIER | MORRANDI GOSTOFF STATES CONTRACTOR AND CONTRACTOR | WITCHELS PRINCE CONTROL TO THE CONTR | THESE-PERSONALIVES THE PERSONALIVES THE PERSON |
| 133 _manthofouns_puthase 132 _manthofouns_puthase 132 _tablesian_puthase 132 _tablesian_puthase 132 _tablesian_puthase 133 _tablesian_puthase 134 _tablesian_puthase 135 _tablesian_put | - PROVIDENTIAL - PROV | SACRETORY CONTROL OF THE STATE | ### ### ### ### ### ### ### ### ### ## | MONOSPICIO DE GOSSESSIONES CONTRACTOR DE CO | WITCHELS PROPRIES OF THE | THESE - TREASURED LANGE OF THE STATE OF THE |
| 133_manthofouna_pythiase 132_manthofouna_pythiase 132_table_name_pythose 132_table_name_pyt | - PROVIDENTIAL PROV | SACREMONING CONTROL OF THE CONTROL O | ### ### ### ### ### ### ### ### ### ## | MORRANDO DE GOSTO PETRA LES CONTRA LES CONTR | WITCHELS PROPRIED TO THE PROPR | TITLE-PURSAYLANING THE - PURSAYLANING THE - PURSAYL |
| 1332_mentodroman_pythams 1332_mentodroman_pythams 1302_table_name_pythams 1302 | - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PROVINCE - PROVIDENTIAL - PR | SAG PRESENTATION CONTROLLED TO THE CONTROLLED TO | ### ### ### ### ### ### ### ### ### ## | MONOSPIELO DE GOSSESSIONES CONTACTO DE CO | WITH THE PROPERTY OF THE PROPE | THESE PURBOUTANTIES THE PURBOUTANTIES THE PURBOUTANTIES HILLY - COVERNITATION HILLY - COVERNITATION THE PURBOUTANTIES THE |
| 1332_mentod-case_problems 1332_mentod-case_problems 1302_telescolor_problems 1302_telescolor_pro | - PROVIDENTIAL PROV | SACREMONING CONTROL OF THE CONTROL O | ### ### ### ### ### ### ### ### ### ## | MORRANDI DOS GOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTO | WITCHELS PROPRIED TO THE PROPR | TITLE-PURBUTANTIAL TITLE-PURBUTA |
| 1332_mentodroman_problems 1332_mentodroman_problems 1302_tablems 1302_ | - PRODUCTION | AMERICAN CALLED STATES OF THE CONTROL OF THE CONTRO | ### ### ### ### ### ### ### ### ### ## | MORRANICA DES GOSTOSTA DEL MANTONIO DE LA CONTRACTION DE LA CONTRA | WITHOUT THE PART OF THE PART O | THESE-PERSONALIVES THE PERSONALIVES THE PERSON |
| 1332_mentodroman_prothess [132_mentodroman_prothess 132_mentodroman_prothess 132_mentodroman_protect 132_mentodroman_protect 132_mentodroman_prothess 133_mentodroman_prothess 133_mentodroman_pr | - PROVIDENCIA | SACREMONING CONTROL OF THE CONTROL O | SERIORATY-OCILIENTS | MORRANDIA DEI GOGGETT STATE MAN DE GOGGETT STATE MA | WITCHELS PROPRIED TO THE PROPR | TITLE-PURBUTANTE THE -PURBUTANTE THE -PURBUTAN |
| 1332_mentodroman_pythams 1302_mentodroman_pythams 1302_mentodroman_pyth | - PROVIDENTIAL - PROV | SAG PRESENTATION CONTROLLED TO THE CONTROL TO THE CONTROLLED TO TH | ### ### ### ### ### ### ### ### ### ## | MORRANIC DOS GOSTOSTATION DE SECRITARIO DE SECRIT | WITH THE PROPERTY OF THE PROPE | THESE PURBOUTANTIES THE PURBOUT |
| 1332_mentodroman_pythams 1302_mentodroman_pythams 1302_mentodroman_pyth | - PROVIDENTIAL - PROV | SAG PRESENTATION CONTROLLED TO THE CONTROL TO THE CONTROLLED TO TH | ### ### ### ### ### ### ### ### ### ## | MORRANIC DOS GOSTOSTATION DE SECRITARIO DE SECRIT | WITH THE PROPERTY OF THE PROPE | THESE PURBOUTANTIES THE PURBOUT |
| 1332_mentodroman_problems (132_mentodroman_problems (132_mentodroman_prob | - PRODUCTION | SAR CHESTORICA DESIGNATION AND AND AND AND AND AND AND AND AND AN | BRIDADIP OLILIBEE SERICE | MORRANDI CON GOODET STATE AND CONTRACT STATE OF THE STATE | WITCHELS AND | THESE-PERSONALATION THESE -PERSONALATION THE -PERSO |
| 1332_mentodroman_pytham 1322_mentodroman_pytham 1322_mentodroman_pyth | - PROVIDENTIAL - PROVINCE | SAG PRESENTATION CONTROLLED TO THE CONTROLLED TO | SERIOLOF - OCILIERES - SERIORI OCICIERES - SERIORI OCILIERES - SERIORI OCICIERES - SERI | MORRANDI DOS GOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTOSTO | WITH COLORS AND | THESE PURBOUTANTIES THE PURBOUT |
| 1332_mentodroman_problems 1302_mentodroman_problems 1302_mentodroman_p | - PRODUCTION | SAR CHESTORICA DESIGNATION AND ADMITTANT AND | BRIDADIP OLILIE EN | MORRANDI DOS GOSPETTA DEL MANDE DE LA CONTRACTA DE LA CONTRACT | WITCHELS PROPRIED TO THE PROPR | THESE-PERSONALATION THESE -PERSONALATION THE -PERSO |
| 1332_mentodroman_pytham 1322_mentodroman_pytham 1322_mentodroman_pyth | - PRODUCTION | SAR CHESTORICAL CONTROLLARS AND | SERIOLOF - OCILIERES - SERIORI OCICIERES - SERIORI OCILIERES - SERIORI OCICIERES - SERI | MORRISHICATION OF CONTROL AND | WITH COLORS AND | THESE PURBOUTANTIES THE PURBOUT |

Figure S1: Amino acid sequence alignment of I10H with characterized and uncharacterized P450s. Asterisk indicate absolutely conserved cysteine residue for coordination of iron. I10H is highlighted in red.





Figure S2: Amino acid sequence alignment of N10OMT with characterized and uncharacterized OMTs. asterisks indicate conserved residues for SAM binding. N10OMT is highlighted in red.






Figure S3: Phylogenetic trees of I10H (TOP) and N10OMT(Bottom) with characterized and uncharacterized proteins. CYP71D12 *C.roseus* tabersonine hydroxylase, T16H; HTOMT CATRO, *C.roseus* 16OMT. I10H and N10OMT are highlighted in red.




Figure S4: SDS-PAGE of recombinant OMTs produced in *Escherichia coli*. The left lane contains molecular weight protein markers and corresponding sizes are indicated to the left of the panel. All other lanes feature purified protein from *E. coli* strain soluBL21. Purification of polyhistidine-tagged recombinant proteins was achieved using a Nickel-affinity column and size exclusion chromatography. Visualization was achieved using Coomassie blue staining.